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Chromophobe renal cell carcinoma (chRCC) is derived from intercalated cells of the 
collecting duct system and comprises approximately 5% of all renal neoplasms. Due to its 
rarity, the very basic molecular characteristics of chRCC on the proteome and metabolome 
level still remain to be investigated. In this thesis, the proteomics and metabolomics 
approaches as well as mitochondrial whole-exome sequencing were employed and 
integrated to gain insights into the mitochondrial DNA (mtDNA) mutation landscape and to 
elucidate pathological alterations between chRCC and adjacent kidney tissues. In addition, 
these results were compared with its benign counterpart, renal oncocytoma (RO), to identify 
molecular differences between these two highly similar tumor subtypes for the discovery of 
potential diagnostic markers. An overall downregulation of the oxidative phosphorylation 
system (OXPHOS) in chRCC was discovered, which is a distinct feature comparing with RO. 
Furthermore, the main ROS scavenger glutathione was boosted in chRCC, as proteins 
involved in glutathione degradation were significantly decreased. Besides, the OXPHOS 
proteins in chRCC were identified to anti-correlate with their corresponding transcripts. The 
decrease of mtDNA content, rather than the complex I mutations, was the main cause of the 
OXPHOS downregulation in chRCC, which sequentially caused the increased glutathione 
level and specifically a poor correlation between the proteins and transcripts of the nuclear- 
but not the mtDNA-encoded OXPHOS subunits. The metabolic reprogramming including the 
classical Warburg effect, the down-regulation of gluconeogenesis and all pathways 
associated with amino acid metabolism was also identified in chRCC. The chRCC cells were 
found to depend on extracellular macromolecules as an amino acid source by activating 
endocytosis, which is probably mediated by phospholipase C gamma 2 (PLCG2). The 
results indicate a direct link between mtDNA depletion, downregulation of OXPHOS and 
subsequently an increase of glutathione in chRCC. In addition, this study provides novel 
insights into the rewiring of metabolic pathways in chRCC and identifies PLCG2 as an 
important player to overcome the nutritional shortage, which might serve as a potential 
therapeutic target for chRCC. The distinct regulation of the OXPHOS between chRCC and 










































Das chromophobe Nierenzellkarzinom (chRCC) leitet sich aus den interkalierten Zellen des 
Sammelkanalsystems ab und macht etwa 5% aller Nierenneoplasmen aus. Aufgrund seiner 
Seltenheit müssen die grundlegenden molekularen Eigenschaften von chRCC auf Proteom- 
und Metabolomebene noch untersucht werden. In dieser Arbeit wurden die Proteome und 
Metabolome sowie die mitochondrialen Sequenzen des Exoms analysiert und integriert, um 
Einblicke in die Mutationslandschaft der mitochondrialen DNA (mtDNA) zu gewinnen und 
pathologische Veränderungen zwischen chRCC und dem benachbarten gesunden 
Nierengeweben aufzuklären. Darüber hinaus wurden diese Ergebnisse mit ihrem gutartigen 
Gegenstück, dem renalen Onkozytom (RO) verglichen, um molekulare Unterschiede 
zwischen diesen beiden sehr ähnlichen Tumorsubtypen zu identifizieren, die potenziell auch 
als diagnostischer Marker verwendet werden können. Es wurde eine generelle 
Herunterregulierung des gesamten oxidativen Phosphorylierungssystems (OXPHOS) in 
chRCC gefunden, was im Vergleich zu RO ein besonderes Merkmal darstellt, da dort 
spezifisch nur CI erniedrigt war. Darüber hinaus wurde der Haupt-ROS-Fänger Glutathion in 
chRCC erhöht gefunden, da Proteine, die am Glutathionabbau beteiligt waren, signifikant 
verringert waren. Außerdem wurde festgestellt, dass die OXPHOS-Proteine in chRCC mit 
ihren entsprechenden Transkripten nicht korrelieren. Die Abnahme des mtDNA-Gehalts 
anstelle der CI-Mutationen war die Hauptursache für die Herunterregulierung von OXPHOS 
in chRCC, die sequenziell den erhöhten Glutathionspiegel und insbesondere eine schlechte 
Korrelation zwischen den Proteinen und Transkripten des Kern-, aber nicht des mtDNA- 
codierte OXPHOS-Untereinheiten verursacht hat. Die metabolische Reprogrammierung 
einschließlich des klassischen Warburg-Effekts, die Herunterregulierung der 
Glukoneogenese und aller mit dem Aminosäuremetabolismus verbundenen 
Stoffwechselwege wurde auch in chRCC identifiziert. Es wurde festgestellt, dass die 
chRCC-Zellen durch Aktivierung der Endozytose, die wahrscheinlich durch Phospholipase C 
gamma 2 (PLCG2) vermittelt wird, von extrazellulären Makromolekülen als 
Aminosäurequelle abhängen. Die Ergebnisse weisen auf einen direkten Zusammenhang 
zwischen der mtDNA-Depletion, der Herunterregulierung von OXPHOS und dem daraus 
resultierenden Anstieg von Glutathion in chRCC hin. Darüber hinaus bietet diese Studie 
neue Einblicke in die Änderung von Stoffwechselwegen in chRCC und identifiziert PLCG2 
als wichtigen Akteur zur Überwindung des Nährstoffmangels, der als potenzielles 
therapeutisches Ziel für chRCC dienen könnte. Die eindeutige Regulation der OXPHOS 










1.1 Renal cell carcinoma 
Renal cell carcinoma (RCC) represents approximately 4% of adult malignancies (Siegel, 
Miller et al. 2019) and was ranked as the sixth deadliest cancer worldwide in 2018 (Bray, 
Ferlay et al. 2018). The American Cancer Society estimated that about 73,820 new RCC 
cases would be diagnosed by the end of 2019 and more than 14,770 deaths would be 
caused by RCC this year in the USA alone (Siegel, Miller et al. 2019). RCC can be classified 
according to distinct morphologic and molecular genetic features and it is composed of 
different subtypes, such as clear cell RCC (ccRCC), papillary RCC (pRCC), chromophobe 
RCC (chRCC), and renal oncocytoma (RO) (Figure 1, Table 1). Many studies have been 
performed recently to characterize RCC to better understand its classification and 
subclassification and to elucidate pathway remodeling in these cancers (Sato, Yoshizato et 
al. 2013, Davis, Ricketts et al. 2014, Cancer Genome Atlas Research, Linehan et al. 2016). 
A new classification concept based on molecular clustering of chromosomes, DNA, RNA, 
miRNA, and protein data was proposed (Cancer Genome Atlas Research, Linehan et al. 
2016, Ricketts, De Cubas et al. 2018), where the organ of origin does not fully determine the 
tumor type as the only factor (Hoadley, Yau et al. 2018). Instead, the cancer classification 
should be based on the similarity of molecular features across different tissue types, which 
was considered more relevant for targeting the same mutations and oncogenic signaling 
pathways (Hoadley, Yau et al. 2018). 
 
Figure 1. Histological sections of different subtypes of renal cell carcinoma.  






Table 1. Incidences and main mutations in subtypes of renal cell carcinoma 






Incidence 75% 5% 10% 5% 5% 
Main mutations VHL MET FH TP53, PTEN mtDNA 
VHL: von Hippel Lindau; MET: MET proto-oncogene; FH: fumarate hydratase; TP53: tumor protein 
P53; PTEN: phosphatase and tensin homolog; mtDNA: mitochondrial DNA. 
1.1.1 Clear cell renal cell carcinoma 
Clear cell RCC (ccRCC) is the most prevalent subtype and accounts for about 75% of all 
RCCs (Table 1) (Moch, Cubilla et al. 2016). It is an aggressive cancer type that originates 
from the proximal convoluted tubule, with a recurrence rate of up to 40% after the initial 
treatment of a localized tumor (Chin, Lam et al. 2006). In its metastatic form, it is associated 
with a high mortality rate (Motzer, Bacik et al. 2004). CcRCC cells have, in general, a clear 
cytoplasm, (which helped coin the name “clear cell”) that is circled by an easily 
distinguishable cell membrane and uniform round nuclei (Figure 1) (Delahunt, Srigley et al. 
2014). About 90% of all ccRCC cases carry mutations in the von Hippel-Lindau (VHL) tumor 
suppressor gene (Cancer Genome Atlas Research 2013, Sato, Yoshizato et al. 2013), 
which was originally identified in a hereditary disease called VHL syndrome (Latif, Tory et al. 
1993). The VHL protein is a target recruitment subunit in an E3 ubiquitin ligase complex and 
recruits the hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions for 
subsequent proteasomal degradation. Thereby, VHL can repress the transcription of more 
than 100 target genes through interaction with HIF1α and HIF1AN, which plays a vital role in 
forming the phenotype of ccRCC (Jaakkola, Mole et al. 2001). HIF1α is a master 
transcription factor that contributes substantially to the regulation of gene expression that is 
dependent on oxygen levels. Under normoxic conditions, VHL interacts with HIF1α and 
hydroxylates the proline residues in the oxygen-dependent degradation (ODD) domains of 
HIF1α by recruiting members of the Egl-nine homolog (EGLN) family (Ivan, Kondo et al. 
2001, Jaakkola, Mole et al. 2001, Gossage, Eisen et al. 2015). With hypoxia or loss of 
function of VHL, these proline residues cannot be hydroxylated, which stabilizes HIF1α. 
Subsequently, HIF1α forms a HIF1α–HIF1β heterodimer, and this dimer translocates into 
the nucleus to enhance the transcription of HIF target genes, which are associated with 
crucial oncogenic pathways, including glucose uptake, glycolysis (e.g., glucose transporter 
type 1, GLUT1), cell proliferation (e.g., epidermal growth factor receptor, EGFR), and 





Riazalhosseini and Lathrop 2016, Posadas, Limvorasak et al. 2017, Wettersten, Aboud et 
al. 2017). 
Furthermore, the gluconeogenic enzyme fructose 1,6-bisphosphatase 1 (FBP1) has been 
found to be decreased in over 600 ccRCC cases and the decreased expression of FBP1 is 
associated with poor disease prognosis. FBP1 has two distinct functions, antagonizing the 
glycolytic flux and inhibiting the nuclear function of HIFα (Li, Qiu et al. 2014), which can 
explain its ubiquitous loss in ccRCC (Li, Qiu et al. 2014). Besides FBP1, the whole 
gluconeogenesis pathway has been shown to be severely diminished in ccRCC at the 
transcriptome (Li, Qiu et al. 2014) and proteome level (Guo, Kouvonen et al. 2015). This 
stimulates the metabolic switch by increasing glycolytic target genes (Li, Qiu et al. 2014), 
which is reflected by the metabolomic analysis of ccRCC, where metabolites in the glycolysis 
pathway show over two-fold increases in abundance compared to the normal kidney (Hakimi, 
Reznik et al. 2016).  
1.1.2 Papillary renal cell carcinoma 
Papillary RCC (pRCC) represents about 15% of all RCCs (Table 1) and derives from the 
proximal convoluted tubule, similar to ccRCC (Moch, Cubilla et al. 2016). It is a less 
aggressive subtype compared to ccRCC and has a high five-year survival rate of 80% to 
85% (Steffens, Janssen et al. 2012). The term “papillary” describes the papilla-like 
protuberances in most of the tumors. It can be further subdivided into type I and type II 
tumors based on morphological features (Figure 1). Type I pRCC is more common and 
shows small fibrovascular papillae that are covered by a single layer of small cuboidal cells 
with scant pale cytoplasm and usually grows slowly (Delahunt and Eble 1997). In contrast, 
type II pRCC consists of papillae, is lined by large columnar pseudostratified cells with 
eosinophilic cytoplasm, and is often more aggressive (Delahunt and Eble 1997, Pignot, Elie 
et al. 2007). Type I and type II pRCC have also been shown to be clinically and biologically 
distinct. Type I is frequently associated with the alterations in the MET pathway (Cancer 
Genome Atlas Research, Linehan et al. 2016, Pal, Ali et al. 2018). The proto-oncogene c-
Met (MET) protein, a transmembrane receptor tyrosine kinase, can bind to its ligand 
hepatocyte growth factor (HGF) and activate several downstream intracellular pathways, 
including focal adhesion kinase (FAK), RAS/RAF/MEK/ERK, and PI3K/AKT (Fay, Signoretti 
et al. 2014). The frequently activating mutations and amplification of MET in type I pRCC 




to promote cancer cell proliferation, angiogenesis, and malignant transformation (Fay, 
Signoretti et al. 2014). 
Frequent mutations in type II pRCC include CDKN2A silencing, SETD2 mutations, and 
TFE3 fusions. Type II tumors are characterized by increased expression of the nuclear 
factor erythroid 2-related factor 2 (NRF2)–antioxidant response element (ARE) pathway 
(Cancer Genome Atlas Research, Linehan et al. 2016). The NRF2–ARE pathway is a major 
regulator of cellular redox balance, and its activation under oxidative stress favors cell 
survival. Furthermore, fumarate hydratase (FH) mutations are also frequently found in type II 
pRCC (Tomlinson, Alam et al. 2002, Li, Shuch et al. 2017). The FH gene encodes a TCA 
cycle enzyme that catalyzes the hydration of fumarate to malate, and its deficiency causes 
fumarate and succinate accumulation (Pollard, Briere et al. 2005, Sullivan, Martinez-Garcia 
et al. 2013). Accumulated fumarate and succinate are believed to be able to suppress the 
hydroxylation of the proline residues in the ODD domain of HIFα, and thus FH mutations in 
type II pRCC also cause the stabilization of HIFα, similarly to ccRCC (Pollard, Briere et al. 
2005, Sullivan, Martinez-Garcia et al. 2013). Some genes (such as CDKN2A/B and TERT) 
where mutations can be found in both types (Pal, Ali et al. 2018) play a pivotal role as tumor 
suppressors by regulating the cell cycle. Mutations of the above-mentioned genes and 
activation of the onco-pathways are the main driver mutations in the progression of pRCC. 
1.1.3 Chromophobe renal cell carcinoma 
Chromophobe RCC (chRCC) accounts for approximately 5% of all RCCs (Table 1) (Moch, 
Cubilla et al. 2016), which is thought to originate from the cortical collecting duct, and was 
first reported in 1985 (Thoenes, Storkel et al. 1985). Different morphological and 
ultrastructural features of the cytoplasm lead to the identification of the classical 
chromophobe and the eosinophilic variant. The cells of the classical type usually have 
abundant clear cytoplasm and a perinuclear halo caused by cytoplasmic organelles being 
pushed away from the center to form a rim along the cell membrane (Figure 1) (Yusenko 
2010). The eosinophilic type has, in general, smaller cells with an inconstant level of 
cytoplasmic organelles in the periphery. Both cell types frequently coexist in chRCC tumors, 
usually with one cell type predominating (Yusenko 2010). One of the most characteristic 
genetic features of chRCC is the monosomy of chromosomes 1, 2, 6, 10, 13, 17, and often 
21 (Brunelli, Eble et al. 2005, Haake, Weyandt et al. 2016, Casuscelli, Weinhold et al. 2017, 
Xiao, Clima et al. 2019). The most commonly mutated genes in chRCC are TP53 (32%), 





Haake, Weyandt et al. 2016). Mutations in these tumor suppressors combined with the 
deletion of one of their chromosomes lead to a complete loss of function. Further mutations 
with a lower frequency were observed in MTOR, NRAS, TSC1, and TSC2, indicating that 
the genomic targeting of the mTOR pathway occurred in 23% of all chRCC (Davis, Ricketts 
et al. 2014). Hence, the anticancer functions of TP53 in apoptosis, genomic stability, and the 
inhibition of angiogenesis and the role of PTEN in the intracellular signaling pathway 
PI3K/AKT/mTOR are both disrupted and can thus be regarded as major driving events in 
these chRCC cases. However, no clear driver mutation was discovered in over 50% of the 
chRCC cases (Davis, Ricketts et al. 2014, Durinck, Stawiski et al. 2015).   
ChRCC was reported to have significantly lower microvessel density compared to the other 
two RCC subtypes, ccRCC and pRCC (Jinzaki, Tanimoto et al. 2000). This is further 
illustrated by the clinical value of 18F-fluorodeoxyglucose-positron emission 
tomography/computed tomography (FDG-PET/CT), which uses a fluorine18 labeled glucose 
analog to image and stage tumors, FDG-PET/CT can be used to access the glucose uptake 
of tumor in vivo. Among the three RCC types, chRCC has a significantly lower level of 
glucose uptake (Figure 2) (Nakajima, Nozaki et al. 2017). Hence, chRCC seems to be 
poorly supported by the blood vessel. As reprogrammed metabolism is a hallmark of cancer 
(Hanahan and Weinberg 2011), how chRCC modifies its fundamental metabolism and 
adapts to the nutrient-poor environment still remains unknown. Due to the comprehensive 
investigation and research focused on ccRCC, extensive metabolic alterations have been 
identified in ccRCC and it has been defined as a metabolic disease (Hakimi, Reznik et al. 
2016, Linehan, Schmidt et al. 2019). On the contrary, even the very basic metabolic 
characteristics of chRCC remain to be investigated.  
 
Figure 2. FDG-PET/CT of ccRCC, pRCC, and chRCC.  
Axial PET/CT images show moderate FDG accumulation in (A: arrow) ccRCC and (B: arrow) pRCC; 
no FDG accumulation was observed in (C) chRCC PET/CT images. Figure adapted from (Nakajima, 




1.1.4 Renal oncocytoma 
Renal oncocytoma (RO) was firstly reported by Zippel in 1942 (Zippel 1941) and is classified 
as benign renal epithelial neoplasm (Lopez-Beltran, Scarpelli et al. 2006, Lopez-Beltran, 
Carrasco et al. 2009). It is derived from intercalated cells of the collecting duct system and 
comprises only a small subset (around 5%) of all renal neoplasms (Table 1). Usually, RO 
can be cured by nephrectomy. RO typically consists of uniform round / polygonal cells with 
abundant, intensely eosinophilic and granular cytoplasm, and with uniformly small, round 
and central nuclei with evenly dispersed chromatin (Figure 1). The two hallmarks of RO are 
the large amount of mitochondria in the cytoplasm (Tickoo, Lee et al. 2000) and the highly 
diminished or complete loss of complex I (CI) enzyme activity within the electron transport 
chain (Simonnet, Demont et al. 2003, Mayr, Meierhofer et al. 2008). The deficiency of CI is 
mainly due to mutations in mitochondrial DNA (mtDNA), particularly, but not exclusively, in 
CI genes (Gasparre, Hervouet et al. 2008, Mayr, Meierhofer et al. 2008). Most mtDNA 
mutations detected in RO are well above the threshold for a pathogenic phenotypic effect 
due to high heteroplasmic load. The mtDNA mutations above the heteroplasmy threshold 
appear to reduce tumor growth because of their impaired effect on respiratory complex 
assembly (Gasparre, Romeo et al. 2011, Ju, Alexandrov et al. 2014). This seems to be the 
main cause of the indolent, low-proliferating, non-invasive behavior of RO.  
1.2 Similarities and differences between chRCC and RO 
ChRCC is considered to be the malignant counterpart of RO (Joshi, Tolkunov et al. 2015), 
as they feature many molecular and histological similarities. Firstly, both of the two tumor 
types are considered to be derived from the same origin, as discussed above. Secondary, 
they both show mtDNA mutations and abnormal mitochondrial pathology. RO has above 
heteroplasmy threshold mtDNA mutations, mainly in CI genes, which leads to its benign 
feature (Gasparre, Romeo et al. 2011, Ju, Alexandrov et al. 2014). ChRCC, on the other 
hand, also has been observed to possess mtDNA mutations in CI genes with a frequency of 
13% (>50% heteroplasmy rate) (Davis, Ricketts et al. 2014). A pathway analysis of the 
transcriptome data showed that cases with mutations in MT-ND5 versus no mutations in this 
gene in chRCC (almost all from the eosinophilic type) lead to an enrichment of the Gene 
Ontology term “mitochondrion” (Davis, Ricketts et al. 2014, Ricketts, De Cubas et al. 2018). 
The eosinophilic chRCC type was even reported to have an increased amount of 
mitochondria, a typical histological feature of RO (Tickoo, Lee et al. 2000). By analyzing the 





which is hypodiploid with loss of chromosome 1, X or Y, and/or 14 and 21 and has a male 
predominance. This subset of RO might be the precursor of the eosinophilic chRCC (Joshi, 
Tolkunov et al. 2015), as the eosinophilic chRCC also has a sex bias and a similar pattern of 
chromosome loss of 1, X, or Y, but with further losses including 2, 6, 10, 13 and 17 (Davis, 
Ricketts et al. 2014, Joshi, Tolkunov et al. 2015). What’s more, a rare cancer susceptibility 
syndrome, called Birt-Hogg-Dubé syndrome (BHDS), caused by germline mutations in the 
FLCN gene (codes for the folliculin protein), is characterized mainly by fibrofolliculomas, 
lung cysts, and renal tumors (Figure 3) (Benusiglio, Giraud et al. 2014, Baba, Schmidt et al. 
2017). Interestingly, the renal tumors in BHDS patients show multiple histological types, 
predominantly (70%) chRCC, RO or hybrid type composed of oncocytic and chromophobe 
elements, very few (9%) even were clear cell type (Hes, Petersson et al. 2013, Benusiglio, 
Giraud et al. 2014, Baba, Schmidt et al. 2017).  
 
Figure 3. Clinical manifestations of Birt-Hogg-Dubé syndrome.  
(A) Fibrofolliculomas on the face (arrow). (B) Histology of fibrofolliculoma showing epithelial strands 
with thick connective tissue stroma (arrows). (C) CT image indicating multiple lung cysts. (D) CT 
image of bilateral multifocal renal tumors(arrowheads). BHDS-associated renal tumors show multiple 
histological types: chromophobe RCC (E), oncocytoma (F), hybrid oncocytic tumor (G), and ccRCC 





1.3 Glutathione salvage pathway in chRCC 
One common characteristic of cancer is the ability to balance the increased level of oxidative 
stress with a high level of antioxidants. Glutathione (GSH), a tripeptide thiol antioxidant 
composed of the amino acids glutamic acid, cysteine, and glycine (Meister 1988), is the main 
reactive oxygen species (ROS) scavenger in cells. GSH is highly reactive and exists in both a 
reduced (GSH) and oxidized disulfide (GSSG) form (Kaplowitz, Aw et al. 1985). The 
predominant form is in the reduced state, which is the most abundant low molecular weight 
thiol in the cells, ranging from 0.5 to 10 mM in most cell types, whereas extracellular GSH 
exists in concentrations lower by magnitudes (Meister and Anderson 1983). The de novo 
biosynthesis of GSH involves two ATP-dependent enzymatic reactions: The first step is 
catalyzed by glutamate-cysteine ligase (GCL), which ligates the amino group of cysteine to 
the γ-carboxylate of glutamic acid to form the dipeptide γ-glutamyl cysteine. The second 
reaction involves GSH synthetase (GSS), which catalyzes a combination of the cysteinyl 
carboxylate of the dipeptide and the amino group of glycine to synthesize GSH (Lu 2009) 
(outlined in Figure 4). 
 
Figure 4. Schematic overview of glutathione (GSH) metabolism.  
Color codes are defined as follows: black = enzymes or transporters; blue = metabolites. GGT: γ-





glutaminase 1; GCL: glutamate-cysteine ligase; GSS: glutathione synthetase. GSSG: glutathione 
oxidized form; ROS: reactive oxygen species. 
γ-glutamyl transferases (GGTs) are membrane-bound, N-terminal nucleophile hydrolases 
that catalyze the breakdown of extracellular GSH and transfer the γ-glutamyl group from 
GSH to produce the constituents glutamate and cysteine, which can be further used for 
intracellular GSH synthesis (Figure 4) (Terzyan, Burgett et al. 2015). Increased serum GGT 
was reported to be a sensitive marker for metastatic ccRCC (Simic, Dragicevic et al. 2007), 
because high GGT level positively correlated with advanced stages, higher grades, and the 
presence of tumor necrosis, and it was further associated with worse survival rates in 
ccRCC patients (Hofbauer, Stangl et al. 2014). One member of the membrane 
transpeptidase family GGT is γ-glutamyl transferase 1 (GGT1), which can remove and 
transfer the γ-glutamyl moiety from extracellular GSH, GSSG, or even GSH conjugates to an 
amino acid acceptor, known as the GSH salvage pathway. This degradation of extracellular 
GSH species fuels the cytoplasm of cells to maintain intracellular GSH levels (Terzyan, 
Burgett et al. 2015). Recent metabolomic profiling studies have identified significantly 
increased amounts of GSH, GSSG, and its precursor γ-glutamyl cysteine in chRCC 
compared to normal kidney tissue (Priolo, Khabibullin et al. 2018, Xiao, Clima et al. 2019). 
Unlike in ccRCC, significantly lower expression of GGT1 has been reported in chRCC 
(Priolo, Khabibullin et al. 2018, Xiao, Clima et al. 2019). The specific loss of GGT1 in chRCC 
leads to an increased sensitivity to oxidative stress, mitochondrial damage, and 
reprogramming of glutamine and glucose metabolism (Priolo, Khabibullin et al. 2018). 
Interestingly, RO was found to have a similar increase in GSH moieties and decreased 
levels of GGT1 relative to normal kidney tissues (Kurschner, Zhang et al. 2017). 
1.4 Glutathione and reactive oxygen species 
Increased ROS levels, including the superoxide anion, hydrogen peroxide, and hydroxyl 
radical, have been reported in many different cancer types. ROS can be either generated by 
genetic alterations and endogenous oxygen metabolism or by exogenous sources, such as 
UV light and radiation. ROS were long thought to be only damaging byproducts of the 
cellular metabolism that can negatively affect DNA, lipids, and proteins (Kim, Kim et al. 
2016). However, more recent studies have highlighted the important role of ROS in cell 
signaling, homeostasis, metabolism, and apoptosis (Kim, Kim et al. 2016).  
GSH is the main ROS scavenger in cells. Besides the classical role of GSH acting as a ROS 




limited to providing a cysteine reservoir (Cho, Johnson et al. 1984), being involved in the 
maturation of iron-sulfur proteins (Sipos, Lange et al. 2002), detoxifying xenobiotics 
(Awasthi, Misra et al. 1983), regulating protein bioactivity by S-glutathionylation (Duan, 
Kodali et al. 2016, Zhang, Liu et al. 2017), and regulating redox signaling (Ren, Zou et al. 
2017). In cancer, GSH plays the role of a double-edged sword in its initiation and 
progression. Moderate ROS levels are widely recognized to trigger cancer initiation and 
progression by inducing mutations and promoting genome instability, eventually activating 
oncogenic signaling pathways that promote cell survival, proliferation, and stress resistance 
(Hussain, Hofseth et al. 2003). On the contrary, massive ROS accumulations can also limit 
cancer growth by causing severe oxidative damage of biomolecules, which finally can lead 
to cell death (Hatem, El Banna et al. 2017). As a consequence, cancer cells are required to 
deliberately balance the levels of ROS and antioxidants (mainly GSH) to maintain redox 
homeostasis, which sustains viability and growth. For many years, one of the most obvious 
therapeutic strategies to overcome new balanced redox homeostasis in renal cell carcinoma 
(RCC) was to fight elevated ROS levels with the supplementation of antioxidants such as 
vitamins to actively force the tumor into apoptosis. Many clinical trials were initiated, and the 
outcomes showed mixed results, including worse survival rates upon supplementation with 
ROS inhibitors (Thyagarajan and Sahu 2018). 
1.5 Hydroethidine based probes for ROS measurement 
As GSH is tightly connected to ROS status, and the rewired metabolism of GSH in RCC has 
been proposed as a hallmark of RCC and can be exploited as a potential treatment strategy 
against RCC (Hakimi, Reznik et al. 2016, Kurschner, Zhang et al. 2017, Ahmad, Paffrath et 
al. 2019, Xiao, Clima et al. 2019, Xiao and Meierhofer 2019). Thus, the ability to assess 
ROS status is of great value, many different methods have been established that allow the 
direct or indirect measurement of redox states, the advantages and disadvantages of these 
methods were reviewed recently (Dikalov and Harrison 2014). One aim of this thesis was to 
develop a robust, rapid and quantitative LC-MS/MS-based method to measure O·2− levels in 
cells. 
The most commonly used fluorogenic probes for O·2− detection, and the current “gold 
standard”, are hydroethidine (HE; or dihydroethidium) and mitochondrial-targeted 
hydroethidine (mito-HE, mitoSOX red) for intracellular and mitochondrial O·2− detection, 
respectively (Zielonka, Hardy et al. 2009, Kalyanaraman, Dranka et al. 2014). Moreover, 





recently developed (Michalski, Zielonka et al. 2013). These three structurally analogous 
fluorogenic probes react with O·2− in a very similar way, wherein O·2−-specific hydroxylated 
products (2-OH-E+, 2-OH-mito-E2+, and 2-OH-Pr2+) are formed as the main products (Figure 
5). However, many other oxidants are present in cells, including redox metal ions, heme 
proteins, and one- or two-electron oxidants, which can give rise to fluorescent ethidium and 
analogs (E+, mito-E2+, and Pr2+) as well as weakly or non-fluorescent dimeric products (di-E+, 
di-mito-E2+, and di-Pr2+; Figure 5) (Kalyanaraman, Dranka et al. 2014). The use of 
fluorescence microscopy or other fluorescence-based methods with these probes should be 
avoided, considering that the fluorescent characteristics of O·2−-derived marker products and 
other non-specific oxidized fluorescent products that form from these probes can have 
spectral overlap (Kalyanaraman, Dranka et al. 2014).  
 
Figure 5. Products formed from HE, mito-HE, and HPr+.  
Figure adapted from (Kalyanaraman, Hardy et al. 2017). 
1.6 Mass spectrometry based metabolomics and proteomics 
1.6.1 Mass spectrometry 
Mass spectrometry (MS) is an analytical technique that can identify and quantify the 
chemicals by ionizing them into ions, sorting the ions according to their mass-to-charge ratio 
(m/z), and then measuring the number of ions. Accordingly, a basic mass spectrometer 
usually consists of at least three parts: an ion source to ionize the chemical species, a mass 
analyzer to sort the ions based on their m/z, and a detector to measure the abundance of 




analyzers to increase its ability to analyze chemical samples. Due to the differences in the 
mass analyzers, there are many different types of mass spectrometers. Here, triple 
quadrupole mass spectrometer (TQMS) and Orbitrap mass spectrometer (OMS), the two 
types of mass spectrometers used in this thesis, are introduced in more details.  
 
Figure 6. Schematic representation of the triple quadrupole mass spectrometer. 
A typical triple quadrupole mass spectrometer (TQMS) consists of an ion source to ionize the 
chemicals, three quadrupoles to act as mass filters (Q1 and Q2) and a collision compartment (Q2), 
and a detector to determine the number of ions. Figure adapted from https://www.biologie.hu-
berlin.de/de/gruppenseiten/oekologie/meth/massspec/mass_sp 
TQMS was firstly developed and constructed by James D. Morrison in 1974 at La Trobe 
University (Morrison 1991).  It is a tandem mass spectrometer composed of three 
quadrupoles in which the first and third quadrupoles (Q1 and Q3) serve as mass filters and 
the second (Q2) acts as a collision cell for collision-induced dissociation (CID) (Figure 6). 
Both Q1 and Q3 contains four parallel, cylindrical metal rods and are controlled by direct 
current (DC) and radio-frequency (RF) potentials to select particular ions to pass through 
them (Dass 2006). The collision cell, Q2, however, can be quadrupole or replaced by 
hexapole or octopole in some instruments to improve efficiency (Dass 2006) and it is only 
controlled by RF potential to fragment ions but allows all ions to pass through (Dass 2006). 
Depending on the purpose of analysis, the TQMS can have at least four different scan 
modes (de Hoffmann 1996, Dass 2006, Domon and Aebersold 2006): Product ion scanning, 
for identifying ion transitions for quantification (Figure 7A). Precursor ion scanning, to select 
the ions with a particular functional group that fragmented in Q2 (Figure 7B). Neutral loss 
scanning, for identifying all the ions with the loss of a given neutral fragment (e.g. 
H2O)(Figure 7C). Multiple reaction monitoring (MRM) mode or selected reaction monitoring 
(SRM), to allow a distinct fragment ion from a certain parent ion to be detected (Figure 7D), 





setting Q1 and Q3 to more than a single mass (ion pairs or transition). Overall, TQMS is 
very robust, cheap, and simple to use, but it only offer low mass resolution and accuracy in 
its application.  
 
Figure 7. Different scan modes of triple quadrupole mass spectrometer. 
The four different scan modes of triple quadrupole mass spectrometer: (A) Product ion scanning; (B) 
Precursor ion scanning; (C) Neutral loss scanning; (D) Multiple reaction monitoring (MRM) mode or 
selected reaction monitoring (SRM). Figure adapted from (Domon and Aebersold 2006). 
Similar to TQMS, the OMS is also a tandem mass spectrometer system (Figure 8), but 
instead of triple quadrupole, it usually contains only two quadruples (can be hexapoles or 
octopoles) acting as the mass filter and collision cell, and another key component, the 
Orbitrap. The Orbitrap is an ion trap mass analyzer consisting of two outer barrel-like 
electrodes and a central spindle-like electrode, enabling it to act as both an analyzer and 
detector (Figure 8). The first Orbitrap was invented by Makarov at the end of the 1990s 
(Makarov 2000). After many years of technical improvement, Thermo Fisher Scientific 
introduced the first commercial Orbitrap analyzer as the core component of a hybrid LTQ 
OMS in 2005 (Makarov, Denisov et al. 2006, Makarov, Denisov et al. 2006). In the Orbitrap, 
the ions are trapped and detected by their image current, and then the detected image 




(Makarov 2000). The OMS has the advantage of high sensitivity and much higher resolution 
compare to TQMS due to the fact that each ion is trapped in the orbitrap and can be 
“counted” more than once (Makarov, Denisov et al. 2006, Makarov, Denisov et al. 2006).  
 
Figure 8. The schematic of an orbitrap mass spectrometer. 
A Q-Exactive Plus Orbitrap mass spectrometer from Thermo Fisher Scientific. The ionized chemicals 
in the ion source are injected into the Orbitrap mass spectrometer, first go through the RF-lens, 
injection flatapole and bent flatapole to reach the segmented quadrupole, here, the ions can be 
selected. The (selected) ions are then injected to C-trap, from here, the ions can either be directly 
transferred into the Orbitrap for analysis (MS1 scan mode), or be further fragmented in the higher-
energy collisional dissociation (HCD) cell and transferred back through the C-trap to the Orbitrap for 
analysis (MS2 scan mode). Figure from https://planetorbitrap.com/q-exactive-plus 
1.6.2 Metabolomics 
Metabolites are the small molecule substrates, which are educts, intermediates, and end 
products of metabolism, they have a multitude of functions, including energy conversion, 
signaling, stimulatory and inhibitory effects on the catalytic activity of enzymes, and 
epigenetic influence (Lu and Thompson 2012, Wellen and Thompson 2012). Metabolomics 
is defined as the systematic study of all chemical processes concerning metabolites by 
measuring the complete set of metabolites present within a biological system, namely, a cell, 
tissue, organ or organism, providing characteristic chemical fingerprints and revealing the 





metabolomics can be divided into two distinct approaches, untargeted and targeted 
metabolomics, both have their own inherent advantages and disadvantages. Untargeted 
metabolomics studies are usually employed to generate hypotheses, focus on acquiring 
data with information as many as possible, the raw data contain all ions within a certain 
mass range, then with software to annotate known and novel metabolites and review both 
known and unknown metabolic changes (Schrimpe-Rutledge, Codreanu et al. 2016). 
Because of the comprehensive and extensive mass spectrum information it contains, 
untargeted metabolomics raw data requires annotation by using in silico libraries or 
experimental investigation and subsequent identification using analytical chemistry (Roberts, 
Souza et al. 2012).  It can be very challenging for using untargeted metabolomics 
approaches due to the time-consuming procedure of massive raw data generation and 
processing, difficulties in identifying unknown metabolites, and the bias towards detection of 
the high-abundance metabolites (Roberts, Souza et al. 2012). On the contrary, targeted 
metabolomics approaches are usually aimed at validating hypothesis by identifying and 
quantifying a limited number of known metabolites, which acquire raw data based on the 
preset ion mass information (usually MRM scanning mode) of known metabolites (Schrimpe-
Rutledge, Codreanu et al. 2016). This approach is much faster, simpler and more robust 
compared to the untargeted metabolomics, as it doesn’t need the comprehensive annotation 
of metabolites, the sample preparation can be optimized to reduce the amount of high-
abundance molecules to avoid bias (Roberts, Souza et al. 2012). In addition, targeted 
metabolomics can be undertaken in a quantitative or semi-quantitative manner, whereas the 
untargeted metabolomics can only be semi-quantitative (Roberts, Souza et al. 2012, 
Schrimpe-Rutledge, Codreanu et al. 2016).   
1.6.3 Proteomics 
Similar to the definition of metabolomics, proteomics is the large-scale study of proteins in a 
biological system (Anderson and Anderson 1998). The word “proteome”, coined by Wilkins, 
et al. in 1994 (Wasinger, Cordwell et al. 1995), was used in his PhD thesis to describe the 
entire complement of proteins expressed by a genome, cell, tissue or organism. There are 
many methods to study the proteome, such as protein chips, reversed-phase protein 
microarrays, two-dimensional gel electrophoresis, and mass spectrometry based 
proteomics. Over the past decades, liquid chromatography coupled with mass spectrometry 
(LC-MS) has gained popularity due to its versatile ability to handle the complexities 





Figure 9. An illustration of data-dependent and data-independent modes of acquisition. 
Two data acquisition strategies of mass spectrometry based proteomics: (A) data-dependent 
acquisition mode, (B) data-independent acquisition mode. Figure adapted from 
http://ajscientific.blogspot.com/2018/04/data-dependent-versus-data-independent.html 
Two general strategies of MS-based proteomics experiments are data-dependent 
acquisition (DDA) and data-independent acquisition (DIA) methods (Figure 9). The DDA 
strategy, which has been very widely used for the last 20 years, is able to provide broad 
detection and quantification of thousands of proteins across various biological samples 
(Mann, Hendrickson et al. 2001, Bateman, Goulding et al. 2014). In recent years, the DIA 
strategy has gained more attention with significant technical improvement.  
In the DDA strategy (Figure 9A), the MS instrument successively isolates the top N most 
abundant precursor ions in a full MS1 spectrum to sequentially acquire their MS2 spectra for 
peptide identification with a database search algorithm (Stahl, Swiderek et al. 1996, Mann, 
Hendrickson et al. 2001). But because of the performance limitation of MS in ion isolation for 
fragmentation and spectra acquisition, DDA strategy can result in losing MS2 spectra 
information of the low abundant precursor ions, which limits the dynamic range of the 





(Figure 9B), on the other hand, was developed to overcome the limitation of DDA by 
continuously collecting MS2 spectra following a complete MS1 spectrum, so that all m/z 
value information at the MS1 and MS2 levels are acquired (Venable, Dong et al. 2004, Gillet, 
Navarro et al. 2012). As the MS2 spectra are collected to contain fragment ions information 
from multiple precursors in this strategy, it is usually very difficult to analyze these mass 
spectra. The Aebersold group developed a method in 2012, called “SWATH-MS”, short for 
Sequential Window Acquisition of All Theoretical Mass Spectra, to analyze the DIA data by 
using a predefined library as a reference, which contains the chromatographic and MS 
behavior of the peptides (Gillet, Navarro et al. 2012). This approach has been used to 
analyze protein samples, total cell lysates and tissue samples for quantification and post-
translational modifications analysis, demonstrated with high reproducibility and accuracy 
(Guo, Kouvonen et al. 2015, Collins, Hunter et al. 2017, Rosenberger, Liu et al. 2017, 
Ludwig, Gillet et al. 2018).   
1.7 Aim of this thesis 
The main aim of this thesis is to characterize chRCC by systematic profiling of the chRCC 
tumors and adjacent healthy kidney tissues with MS-based proteomics and targeted 
metabolomics technologies as well as mitochondrial whole-exome sequencing. By 
integrative analysis of these omics data, I hope to reveal new molecular pathological 
mechanisms of this tumor. In this thesis, the proteome, metabolome data, and the 
mitochondrial mutations of nine chRCC cases were reported and analyzed. In addition, 
comparative analyses with the existing chRCC transcriptome data as well as the published 
omics data of RO (Kurschner, Zhang et al. 2017) were conducted to identify distinguishing 
markers of these two highly similar tumor types. Ultimately, the findings of this thesis will 
help in a more accurate diagnosis of this disease and will lead to the development of novel 













2. Materials and methods 
2.1 List of buffers 
2.1.1 Buffers for proteome profiling 
Sodium deoxycholate (SDC) lysis buffer for tissue samples 
 1% (w/v) SDC 
 10 mM tris(2-carboxyl)phosphine (TCEP) 
 40 mM chloroacetamide (CAA) 
 100 mM Tris  
 Adjust the pH to 8.5. 
 
Guanidinium chloride (GdmCl) cell lysis buffer for cell samples 
 6M GdmCl 
 100 mM Tris-HCl 
 10 mM TCEP 
 40 mM CAA 
2.1.2 Buffers for enzymatic activity measurement 
Sucrose homogenization buffer  
 20 mM Tris-HCl  
 40 mM KCl   
 2 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA)   
 250 mM sucrose  
 Adjust the pH to 7.4, and add sucrose shortly before use. 
 
PBS buffer (0.5 M, pH 7.5) 
 Titrate 0.5 M K2HPO4 buffer with 0.5 M KH2PO4 buffer up to a pH of 7.5. Store at 4 
°C for up to 2 months. 
 
PBS buffer (0.1 M, pH 7.0) 
 Titrate 0.1 M K2HPO4 buffer with 0.1 M KH2PO4 buffer up to a pH of 7.0. Store at 4 





Tris buffer with Triton X-100  
 200 mM Tris  
 0.2% (v/v) Triton X-100 
 Adjust the pH to 8.0 with HCl. Store at 4 °C for up to 2 months. 
 
Reduced cytochrome c solution (1 mM) 
 1 mM cytochrome c solution (oxidized status) 
 In order to reduce the protein, add 5 µl of the 0.5 M dithiothreitol solution to 1 ml of 1 
mM cytochrome c solution and mix gently, and wait for 15 minutes. The color of the 
solution should go from dark orange-red to pale purple-red. Measure the A550/A565 
ratio of an aliquot diluted 20-fold with 1× assay buffer (50 µl in 950 µl of 1× Assay 
Buffer). Use the 1× assay buffer to zero the spectrophotometer. The A550/A565 ratio 
should be over 6.   
 
Decylubiquinol solution (2.5 mM) 
 Add a few grains of sodium borohydride to 600 µl of 2.5 mM decylubiquinone 
solution in ethanol. Add 5-µl aliquots of 0.1 M HCl until the solution becomes 
colorless. Briefly spin the solution at 10,000g for 1 min and transfer the solution into 
a new 500-µl tube, avoiding any sodium borohydride crystals. Adjust the pH of the 
solution between 2 and 3 with 5-µl aliquots of 1 M HCl and keep the solution on ice 
protected from light.  
Note: This solution should be freshly prepared. Caution: Sodium borohydride is highly 
toxic, avoid skin contact and inhalation. 
 
4-Nitrophenyl N-acetyl-β-D-glucosaminide substrate solution (1 mg/ml) 
 10 mg 4-Nitrophenyl N-acetyl-β-D-glucosaminide  
 10 ml of citrate buffer (0.09 M, pH 4.5) 
 Mix the solution with rocking/shaking on a horizontal shaker at room temperature.   
Note: The substrate does not easily dissolve in the buffer. It may take around 1 hour of 
shaking to completely dissolve the substrate. The use of a larger container (50 ml) may 
aid dissolution. The substrate solution should be stored on ice during the experiment. 
For longer storage of at least one month, store at -20 °C. 




2.1.3 Buffers for western blot 
Running buffer 
 25 mM Tris 
 192 mM glycine 
 0.1% (w/v) SDS 
 Mix well until all the materials dissolved, adjust the pH to 7.6 before use. 
 
Transfer buffer 
 25 mM Tris 
 192 mM glycine 
 20 % (v/v) methanol 
 0.1% (w/v) SDS 
 Mix well until all the materials dissolved and adjust the pH to 8.3 before use.  
 
TBST buffer 
 15 mM Tris-HCl  
 4.6 mM Tris 
 150 mM NaCl 
 0.1% (v/v) Tween 20 
 Mix well until all the materials dissolved, adjust the pH to 7.6 before use.  
  
Blocking buffer 
 5% (w/v) BSA in TBST buffer 
 Mix well until all the materials dissolved.  
2.2 Cell culture 
The chromophobe RCC cell line UOK276 (Yang, Vocke et al. 2017) was provided by Dr. W. 
Marston Linehan from the National Cancer Institute, the United States of America. The 
UOK276  and the human kidney (HK-2, cortex/proximal tubule, ATCC CRL-2190) cell line 
were cultivated in Dulbecco's Modified Eagle Medium (DMEM; Life Technologies, New York, 
NY, USA) containing 4.5 g/L glucose, supplemented with 10% fetal bovine serum (FBS; 
Sigma-Aldrich, St. Louis, MO, USA) and 1% penicillin-streptomycin-neomycin (PSN; 




For the proliferation assays, UOK276 and HK-2 cells were seeded in 96-well plates at a 
density of 2×104 cells per well in complete medium. After 12 hours, cells were briefly rinsed 
and cultured in minimum essential medium (MEM; Thermo Fisher, Waltham, MA, USA) 
supplemented with 10% dialyzed FBS (Thermo Fisher), amino acid (AA; 0, 1, and 10% 
versus 100% relative to the AA level in MEM; Thermo Fisher), and bovine serum albumin 
(BSA; 0 and 2.5% total, Sigma-Aldrich) concentrations. The number of cells was determined 
with the cell counting kit 8 (Sigma-Aldrich) after 4 days.  
2.3 Tissue dissection and verification of chRCC 
Nine pairs of chRCC and their non-malignant counterparts derived from nephrectomies at 
the Charité – Universitätsmedizin Berlin were collected in liquid nitrogen immediately after 
surgery and preserved at -80°C. The clinical characteristics of the tumors are reported in 
Table 2. From the collected tissue samples, histologic sections were stained with 
hematoxylin and eosin. The diagnosis of chRCC and the corresponding matched tumor-free 
kidney tissue was done according to the WHO classification criteria. Only cases with a clear 
diagnosis of chRCC were considered for the study. 







Grade Tumor Size 
(Max Dimension) 
Nephrectomy 
C1 49 Female pT1a 2 28 mm radical, left 
C2 37 Female pT2a 2 75 mm  radical, right 
C3 42 Female pT2a 2 98 mm radical, left 
C4 50 Male pT3a 2 100 mm  radical, right 
C5 71 Female pT3a 3 70 mm radical, right 
C7 38 Female pT1b 1 60 mm partial, right 
C8 58 Male pT1b 1 65 mm radical, left 
C9 36 Female pT2b 2 110 mm radical, left 
C10 46 Male pT2a 0 74 mm radical, right 
2.4 Proteomics 
2.4.1 Sample preparation for proteome profiling 
The tissue samples for proteomics were processed with iST 96X kits following the 
manufacturer’s protocol (iST sample preparation kit 96X, PreOmics, Martinsried, Germany). 
Briefly, tissues were homogenized under denaturing conditions with a FastPrep (three times 
for 60 s, 6.5 mx s-1), followed by boiling at 95°C for 10 min. The lysates containing 40 µg 
protein were then digested by trypsin and Lys-C protease mixture at 37 ◦C overnight. 




Subsequently, the peptides were purified with the cartridge and each sample was further 
separated using three fractions according to (Kulak, Pichler et al. 2014). A total of 10 µg of 
each fraction was analyzed by LC-MS for proteome profiling. All fractions were allocated to 
the corresponding replicate and analyzed jointly by the software tool MaxQuant (Cox and 
Mann 2008). 
Proteomic profiling of the UOK276 cells was done as reported previously (Kurschner, Zhang 
et al. 2017) in biological triplicates. In the control group, the UOK276 cells were grown in 
100% AA medium (relative to the AA level of MEM), in the treatment group, the medium was 
modified to contain only 1% AA (relative to the AA level of MEM), but supplied with 2.5 % 
BSA. The comparison proteomics was to investigate the global change of UOK276 cells on 
the proteome level when under nutrient-poor conditions.  
2.4.2 LC-MS instrument settings and data analysis 
LC−MS/MS was carried out by nanoflow reverse-phase liquid chromatography (Dionex 
Ultimate 3000, Thermo Fisher) coupled online to a Q-Exactive HF Orbitrap mass 
spectrometer (Thermo Fisher). Briefly, the LC separation was performed using a PicoFrit 
analytical column (75 μm ID × 55 cm long, 15 µm Tip ID (New Objectives, Woburn, MA) in-
house packed with 3-µm C18 resin (Reprosil-AQ Pur, Dr. Maisch, Ammerbuch-Entringen, 
Germany). Peptides were eluted using a gradient from 3.8 to 40% solvent B in solvent A 
over 120 min at 266 nL per minute flow rate. Solvent A was 0.1 % formic acid and solvent B 
was 79.9% acetonitrile, 20% H2O, 0.1% formic acid. Nanoelectrospray was generated by 
applying 3.5 kV. A cycle of one full Fourier transformation scan mass spectrum (300−1750 
m/z, resolution of 60,000 at m/z 200, AGC target 1e6) was followed by 16 data-dependent 
MS/MS scans (resolution of 30,000, AGC target 5e5) with a normalized collision energy of 
27 eV. In order to avoid repeated sequencing of the same peptides, a dynamic exclusion 
window of 30 sec was used. In addition, only peptide charge states between two to eight 
were sequenced. 
Raw MS data were processed with MaxQuant software (v1.6.0.1) (Cox and Mann 2008) and 
searched against the human proteome database UniProtKB with 70,941 entries, released in 
01/2017. Parameters of MaxQuant database searching were: A false discovery rate (FDR) 
of 0.01 for proteins and peptides, a minimum peptide length of 7 amino acids, a mass 
tolerance of 4.5 ppm for precursor and 20 ppm for fragment ions were required. A maximum 
of two missed cleavages was allowed for the tryptic digest. Cysteine carbamidomethylation 




set as variable modifications. MaxQuant processed output files can be found in 
Supplemental Table S1, showing peptide and protein identification, accession numbers, % 
sequence coverage of the protein, q-values, and LFQ intensities. Contaminants, as well as 
proteins identified by site modification and proteins derived from the reversed part of the 
decoy database, were strictly excluded from further analysis. 
2.4.3 Gene set enrichment analysis 
For comprehensive proteome data analyses, gene set enrichment analysis (GSEA, v3.0) 
(Subramanian, Tamayo et al. 2005) was applied in order to see, if a priori defined sets of 
proteins show statistically significant, concordant differences between chRCC and kidney 
tissues. Only proteins with valid values in at least six of nine samples in at least one group 
with replacing missing values from the normal distribution for the other group were used 
(Supplemental Table S2). GSEA default settings were applied, except that the minimum size 
exclusion was set to 5 and KEGG v5.2 was used as a gene set database. The cut-off for 
significantly regulated pathways was set to a p-value ≤ 0.01 and FDR ≤ 0.15. 
2.5 Metabolomics 
2.5.1 Metabolites extraction and reconstitution 
About 30 mg of 10 unrelated and N2 shock froze chRCC and corresponding healthy kidney 
tissues were used for metabolite profiling. Metabolite extraction and tandem LC-MS 
measurements were done as previously reported (Meierhofer, Halbach et al. 2016, 
Kurschner, Zhang et al. 2017). In brief, methyl-tert-butyl ester (MTBE, Sigma-Aldrich), 
methanol, ammonium acetate, and water were used for metabolite extraction. Each cut 
tissue was homogenized first in 1.5 ml of methanol plus 0.2 ml of ammonium acetate, then 
15 µl of in-house internal standard mix (containing 30 pmol/L 13C labeled glutamine, uracil, 
arginine, proline, valine, and unlabeled chloramphenicol), 5 ml of MTBE and 1.25 ml of LC-
grade water were sequentially added into each replicate and incubated at room temperature 
(RT) for 1 hour at 1000 rpm in a thermal mixer, and then centrifuged for 10 minutes at 1,000 
g at 4°C to achieve phase separation. The upper organic phase and lower aqueous phase 
were transferred and divided into three equal aliquots, and combined into three new tubes, 
so all the tubes contain an equal amount of organic and aqueous phases. The extracted 
metabolites in tubes were then air-dried in a SpeedVac and stored at -80°C before 
reconstitution. (All the debris from the interlayer and pellets were carefully avoided and kept 
at -80°C for DNA isolation.)  




The three dried metabolite aliquots were reconstituted in 50 µl of H2O, methanol, and 68% 
acetonitrile in methanol, respectively. For the metabolites re-dissolved in 68% acetonitrile in 
methanol, 1.5 µl of Avanti Sph/Cer mix standard (Avanti, 25 µM stock, Alabaster, AL, USA) 
was added. All the reconstituted samples were sonicated twice in the ice-cold water bath for 
5 minutes to ensure complete dissolve of the metabolites. After sonication, the samples 
were centrifuged at 18,000 g for 10 minutes and the 5 µl of the supernatant was injected into 
LC-MS/MS for measurement. 
2.5.2 Metabolome profiling by targeted LC-MS 
The subsequent separation was performed on an LC instrument (1290 series UHPLC; 
Agilent, Santa Clara, CA, USA), online coupled to a triple quadrupole hybrid ion trap mass 
spectrometer QTrap 6500 (Sciex, Foster City, CA, USA), as reported previously (Gielisch 
and Meierhofer 2015). Transition settings for multiple reaction monitoring (MRM) are 
provided in Supplemental Table S4. The metabolite identification was based on three levels: 
(i) the correct retention time, (ii) up to three MRM’s and (iii) a matching MRM ion ratio of 
tuned pure metabolites as a reference (Gielisch and Meierhofer 2015). Relative 
quantification was performed using MultiQuantTM software v.2.1.1 (Sciex). The integration 
setting was a peak splitting factor of 2 and all peaks were reviewed manually. Only the 
average peak area of the first transition was used for calculations. Normalization was done 
according to used amounts of tissues and subsequently by internal standards, as indicated 
in Supplemental Table S4.  
2.6 Analysis of TCGA chRCC RNA-seq data 
TCGA (ID: KICH) RNA-seq data were obtained from UCSC Xena (Goldman, Craft et al. 
2019) (https://xenabrowser.net/). Accurate transcript quantification of chRCC (n=66) and 
controls (n=25) was based on the RNA-Seq by Expectation Maximization (RSEM) method 
(Li and Dewey 2011). 
2.7 Whole exome sequencing and mitochondrial bioinformatics analysis 
DNA was isolated from the remaining pellets after metabolite extraction with a DNA 
purification kit according to the manufacturer’s protocol (QIAmp DNA Mini Kit for Tissues, 
Qiagen, Hilden, Germany). In brief, the pellets were lysed by proteinase K and the RNA was 
removed by RNase, the RNA-free genomic DNA was then purified and eluted on QIAamp 




to Agilent’s SureSelect protocol (SureSelectXT Human All Exon V5, protocol version B4 
August 2015) for Illumina paired-end sequencing, as reported previously (Kurschner, Zhang 
et al. 2017). The fastq files were used as input for the MToolBox pipeline (Calabrese, 
Simone et al. 2014), in order to extract mitochondrial DNA sequences and quantify each 
variant allele heteroplasmy, as done previously (Kurschner, Zhang et al. 2017).  
2.8 Measurement of the enzyme activities 
2.8.1 Sample preparation for enzyme activity measurement 
Sample preparation for spectrophotometric assay enzyme activity was done as reported 
previously (Gielisch and Meierhofer 2015). In brief, approximately 5 mg of the tumor and 
healthy kidney tissues were homogenized in sucrose homogenization buffer and centrifuged 
at 600 g at 4 °C for 10 min. The protein concentrations of supernatants were further 
determined with a bicinchoninic acid (BCA) assay (Thermo Fisher). For complex I, II, and V, 
4 µg protein of each sample was used for the enzymatic activity measurement; for complex 
III, IV, and citrate synthase, 2 µg protein was used. Rotenone (10 µM), malonic acid (5 mM), 
antimycin A (5 µg/ml), potassium cyanide (500 µM), and oligomycin (5 µg/ml) served as 
specific inhibitors for complex I to V, respectively. The enzymatic activities of the 
hexosaminidases A and B were assayed as previously described by using 4-nitrophenyl N-
acetyl--D-glucosaminide as an artificial substrate (Shibata and Yagi 1996). 4 µg protein for 
the tissue samples and 1.5 µg for cell samples were used for the hexosaminidases A and B 
assay. Heat inactivation of hexosaminidase B was performed by pre-incubation of samples 
for 3 h at 48 °C (Grabowski, Kruse et al. 1984). The detailed protocols for individual enzyme 
activity measurement were listed as follows:  
2.8.2 Enzymatic activity measurement of Complex I 
 Prepare the buffers to detect the complex I activity (for 70 samples): 
Complex I buffer (14 ml): 
9.8 ml H2O 
1.4 ml PBS (0.5 M, pH 7.5) 
840 µl 50 mg/ml BSA solution 
420 µl 10 mM KCN solution 
140 µl 10 mM NADH solution 
Mix the above solution evenly and well in a 15 ml Falcon tube, put on ice before use; 
420 µl 2 mM ubiquinone Q1 solution 




700 µl 0.2 mM rotenone solution 
 Add 10 µl of tissue homogenate to the well of a 96-well plate,  for each well, add 200 
µl complex I buffer, incubate at 37 °C and read the absorbance at 340 nm for 5 min; 
 Start the reaction by adding 6 µl of 2 mM ubiquinone Q1 solution, monitor the 
absorbance at 340 nm for 5 min.  
 Stop the reaction by adding 10 µl 0.2 mM rotenone solution, monitor the absorbance 
at 340 nm for another 5 min.  
 To calculate the enzymatic activity of complex I, the values of the Δ change of 
absorbance per minute after rotenone addition was subtracted from values of the Δ 
change of absorbance per minute total, the equation of calculating the enzymatic 
activity: 
Activitycomplex I (nmol/min/mg) = 
[Δ𝐴340(𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑟𝑜𝑡𝑒𝑛𝑜𝑛𝑒)−Δ𝐴340(𝑤𝑖𝑡ℎ 𝑟𝑜𝑡𝑒𝑛𝑜𝑛𝑒)]×1000 
𝜀(𝑚𝑀−1𝑐𝑚−1)×𝑡𝑖𝑚𝑒(𝑚𝑖𝑛)×𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑎𝑚𝑜𝑢𝑛𝑡(𝑚𝑔)
 
The extinction coefficient (ɛ) for NADH at 340 nm is 6.2 mM-1 cm-1 (Spinazzi, Casarin 
et al. 2012). 
2.8.3 Enzymatic activity measurement of Complex II 
 Prepare the buffers to detect the complex II activity (for 70 samples): 
Complex II buffer (14 ml): 
9.87 ml H2O 
700 µl PBS (0.5 M, pH 7.5) 
280 µl 50mg/ml BSA solution 
420 µl 10 mM KCN solution 
700 µl 400 mM succinate solution 
2.03 ml 0.015% (w/v) 2, 6-dichlorophenolindophenol (DCPIP) sodium solution 
Mix the above solution evenly and well in a 15 ml Falcon tube, put on ice before use; 
280 µl 2.5 mM decylubiquinone solution 
700 µl 0.1 M malonic acid solution 
 Add 10 µl of tissue homogenate to the well of a 96-well plate,  for each well, add 200 
µl complex II buffer, incubate at 37 °C and read the absorbance at 600 nm for 5 min; 
 Start the reaction by adding 4 µl of 2.5 mM decylubiquinone solution, monitor the 
absorbance at 600 nm for 5 min.  
 Stop the reaction by adding 10 µl 0.1 M malonic acid solution, monitor the 




 To calculate the enzymatic activity of complex II, the values of the Δ change of 
absorbance per minute after malonic acid addition was subtracted from values of the 
Δ change of absorbance per minute total, the equation of calculating the enzymatic 
activity: 
Activity complex II (nmol/min/mg) = 
[Δ𝐴600(𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑚𝑎𝑙𝑜𝑛𝑖𝑐 𝑎𝑐𝑖𝑑)−Δ𝐴600(𝑤𝑖𝑡ℎ 𝑚𝑎𝑙𝑜𝑛𝑖𝑐 𝑎𝑐𝑖𝑑)]×1000 
𝜀(𝑚𝑀−1𝑐𝑚−1)×𝑡𝑖𝑚𝑒(𝑚𝑖𝑛)×𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑎𝑚𝑜𝑢𝑛𝑡(𝑚𝑔)
 
The extinction coefficient (ɛ) for DCPIP at 600 nm is 19.1 mM-1 cm-1 (Spinazzi, 
Casarin et al. 2012). 
2.8.4 Enzymatic activity measurement of Complex III 
 Prepare the buffers to detect the complex III activity (for 70 samples): 
Complex III buffer (14 ml): 
11.13 ml H2O 
750 µl PBS (0.5 M, pH 7.5) 
1050 µl 1 mM oxidized cytochrome C solution 
700 µl 10 mM KCN solution 
280 µl 5 mM EDTA solution 
140 µl 2.5% (w/v) Tween-20 solution 
Mix the above solution evenly and well in a 15 ml Falcon tube, put on ice before use; 
560 µl 2.5 mM decylubiquinol solution 
700 µl 0.1 mg/ml antimycin A solution 
 Add 10 µl of tissue homogenate to the well of a 96-well plate,  for each well, add 200 
µl complex III buffer, incubate at 37 °C and read the absorbance at 550 nm for 5 min; 
 Start the reaction by adding 8 µl of 2.5 mM decylubiquinol solution, monitor the 
absorbance at 550 nm for 5 min.  
 Stop the reaction by adding 10 µl of 0.1mg/ml antimycin A solution, monitor the 
absorbance at 550 nm for another 5 min.  
 To calculate the enzymatic activity of complex III, the values of the Δ change of 
absorbance per minute after antimycin A was added was subtracted from values of 
the Δ change of absorbance per minute total, the equation of calculating the 
enzymatic activity: 
Activity complex III (nmol/min/mg) = 
[Δ𝐴550(𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑎𝑛𝑡𝑖𝑚𝑦𝑐𝑖𝑛 𝐴)−Δ𝐴550(𝑤𝑖𝑡ℎ 𝑎𝑛𝑡𝑖𝑚𝑦𝑐𝑖𝑛 𝐴)]×1000 
𝜀(𝑚𝑀−1𝑐𝑚−1)×𝑡𝑖𝑚𝑒(𝑚𝑖𝑛)×𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑎𝑚𝑜𝑢𝑛𝑡(𝑚𝑔)
 




The extinction coefficient (ɛ) for reduced cytochrome C at 550 nm is 18.5 mM-1 cm-1 
(Spinazzi, Casarin et al. 2012). 
2.8.5 Enzymatic activity measurement of Complex IV 
 Prepare the buffers to detect the complex IV activity (for 70 samples): 
Complex IV buffer (14 ml): 
6.16 ml H2O 
7 ml PBS (0.1 M, pH 7.0) 
840 µl 1mM reduced cytochrome C solution 
Mix the above solution evenly and well in a 15 ml Falcon tube, put on ice before use; 
420 µl 10 mM KCN solution 
 Add 10 µl of tissue homogenate to the well of a 96-well plate,  for each well, add 200 
µl complex IV buffer, incubate at 37 °C and read the absorbance at 550 nm for 5 
min; 
 Stop the reaction by adding 6 µl of 10 mM KCN solution, monitor the absorbance at 
550 nm for another 5 min.  
 To calculate the enzymatic activity of complex IV, the values of the Δ change of 
absorbance per minute after KCN addition was subtracted from values of the Δ 
change of absorbance per minute total, the equation of calculating the enzymatic 
activity: 
Activity complex IV (nmol/min/mg) = 
[Δ𝐴550(𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝐾𝐶𝑁)−Δ𝐴550(𝑤𝑖𝑡ℎ 𝐾𝐶𝑁)]×1000 
𝜀(𝑚𝑀−1𝑐𝑚−1)×𝑡𝑖𝑚𝑒(𝑚𝑖𝑛)×𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑎𝑚𝑜𝑢𝑛𝑡(𝑚𝑔)
 
The extinction coefficient (ɛ) for reduced cytochrome C at 550 nm is 18.5 mM-1 cm-1 
(Spinazzi, Casarin et al. 2012). 
2.8.6 Enzymatic activity measurement of Complex V 
 Prepare the buffers to detect the complex V activity (for 70 samples): 
Complex V buffer (14 ml): 
5.8 µl lactate dehydrogenase (final concentration 4 U/ml); 
17.5 µl pyruvate kinase (final concentration 4 U/ml) 
280 µl 10 mM NADH solution; 
140 µl 200 mM phosphoenolpyruvic acid solution; 
140 µl 100 mM ATP solution; 
280 µl 50mg/ml BSA solution; 




140 µl 300 µM carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone solution; 
Then add Tris (40 mM, pH 8.0) with 5 mM MgCl2 and 10 mM KCl to a final volume of 
14 mL, mix the above solution evenly and well in a 15 ml Falcon tube, put at 37 °C 3 
min before use; 
700 µl 0.1 mg/ml oligomycin solution 
 Add 10 µl of tissue homogenate to the well of a 96-well plate,  for each well, add 200 
µl complex V buffer, incubate at 37 °C and read the absorbance at 340 nm for 5 min; 
 Stop the reaction by adding 10 µl of 0.1 mg/ml oligomycin solution, monitor the 
absorbance at 340 nm for another 5 min.  
 To calculate the enzymatic activity of complex V, the values of the Δ change of 
absorbance per minute after oligomycin addition was subtracted from values of the Δ 
change of absorbance per minute total, the equation of calculating the enzymatic 
activity: 
Activity complex V (nmol/min/mg) = 
[Δ𝐴340(𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑜𝑙𝑖𝑔𝑜𝑚𝑦𝑐𝑖𝑛)−Δ𝐴340(𝑤𝑖𝑡ℎ 𝑜𝑙𝑖𝑔𝑜𝑚𝑦𝑐𝑖𝑛)]×1000 
𝜀(𝑚𝑀−1𝑐𝑚−1)×𝑡𝑖𝑚𝑒(𝑚𝑖𝑛)×𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑎𝑚𝑜𝑢𝑛𝑡(𝑚𝑔)
 
The extinction coefficient (ɛ) for NADH at 340 nm is 6.2 mM-1 cm-1 (Spinazzi, Casarin 
et al. 2012). 
2.8.7 Enzymatic activity measurement of citrate synthase 
 Prepare the buffers to detect the citrate synthase activity (for 70 samples): 
Citrate synthase buffer (14 ml): 
5.18 ml H2O 
7 ml Tris buffer (200 mM, pH 8.0) with 0.2% (v/v) Triton X-100 
1.4 ml 1 mM 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) solution 
420 µl 10 mM acetyl CoA solution 
Mix the above solution evenly and well in a 15 ml Falcon tube, put on ice before use; 
700 µl 10 mM oxaloacetic acid solution 
 Add 10 µl of tissue homogenate to the well of a 96-well plate,  for each well, add 200 
µl citrate synthase buffer, incubate at 37 °C and read the absorbance at 412 nm for 5 
min; 
 Start the reaction by adding 10 µl of 10 mM oxaloacetic acid solution, monitor the 
absorbance at 412 nm for 5 min.  




 To calculate the enzymatic activity of citrate synthase, the values of the Δ change of 
absorbance per minute after oxaloacetic acid addition was used, the equation of 
calculating the enzymatic activity: 




The extinction coefficient (ɛ) for DTNB at 412 nm was 13.6 mM-1 cm-1 (Ellman 1958). 
2.8.8 Enzymatic activity measurement of hexosaminidase A and B 
 Equilibrate all the solutions to 37 °C by incubating for several minutes.  
 Set the spectrophotometry plate reader at 400 nm.  
 Add 10 µl sample and then 90 µl of 1 mg/ml 4-nitrophenyl N-acetyl-β-D-
glucosaminide substrate solution to the 96-well plates and mix using a horizontal 
shaker or by pipetting, measure the absorption at 400 nm immediately at time 0. 
 Incubate the plate for 5-10 minutes at 37 °C. If one suspects that the total beta-
hexosaminidase activity of the test sample may be low, the incubation time can be 
extended up to 30 minutes. (The tissue samples were incubated for 20 minutes, cell 
samples 30 minutes) 
 Stop the reactions by adding 200 µl of 400 mM sodium carbonate buffer to each well, 
and then measure the absorption at 400 nm. 
 Calculate the total enzyme activity with the following equation:  




The extinction coefficient (ɛ) for 4-nitrophenoxide at 400 nm was 18.6 mM-1 cm-1 
(Shibata and Yagi 1996).  
 After pre-incubating the samples for 3 hours at 48°C (Grabowski, Kruse et al. 1984) 
to inactivate hexosaminidase B, measure the hexosaminidase A activity by following 
the same protocol as the total enzyme activity measurement. 
 Calculate the hexosaminidase B activity with the following equation:  
Activity hexosaminidase B = Activity total - Activity hexosaminidase A 
2.9 Determination of free and total GSH in plasma and urine  
(This part was done by the colleagues from Charité - Universitätsmedizin Berlin.) 
Since the increased GSH level is a hallmark in RO and chRCC tissues, I wondered, if this 
was also reflected in plasma and urine to establish a non-invasive metabolic marker. 




specimens (8 RO, 20 ccRCC, 19 pRCC, 7 chRCC, and 20 healthy) were investigated. Free 
and total GSH was measured using a glutathione fluorescent detection kit according to the 
manufacturer’s protocol (Invitrogen).  
2.10 The ethidium bromide treated UOK276 cells as an mtDNA depletion cell 
model 
The UOK276 cells cultured in normal medium (DMEM supplemented with 10% FBS and 1% 
PSN) were seeded into T75 flask in triplicates. 24 hours after plating cells, the medium was 
supplemented with 100 ng/ml ethidium bromide (EtBr) to induce mtDNA depletion. The cells 
were then seeded into 6-well plates, on day 0, 2, 5, 8, 13, 19, the treated cells were 
collected and frozen immediately at -80°C for the measurement of GSH level, mtDNA, RNA 
and protein correlation. 
2.10.1 GSH extraction in ethidium bromide treated cells 
The EtBr treated cells in 6-well plates were took out from -80°C, immediately, 1 ml ice-cold 
methanol/chloroform (9/1, v/v) mix solution was added to each well to extract GSH from the 
cells. Then the 6-well plates were incubated on ice for 5 minutes, and the cells were scraped 
off by cell scraper and collected into a new 1.5 ml tube. The collected samples were then 
centrifuged at 10, 000 g for 10 minutes at 4°C, the precipitated pellets were kept for DNA 
isolation, and the supernatants were air-dried in speed-Vac and then re-dissolved by adding 
85 µl 80% acetonitrile with 3 µM chloramphenicol (as internal standard), 20 µl re-dissolved 
sample was injected into the LC-MS system for analysis.  
2.10.2 Relative quantification of mtDNA content by qPCR 
2.10.2.1 DNA isolation  
The remaining pellets after GSH extraction were used for genomic DNA isolation. The DNA 
isolation was done by using a QIAamp DNA micro kit according to the manufacturer’s 
protocol (QIAmp DNA Micro Kit, Qiagen). The purified DNA was quantified by using the 
NanoDrop 1000 spectrophotometer (Thermo Fisher). 
2.10.2.2 Confirmation of the ρ0 status by qPCR 
The depletion of mtDNA in EtBr treated cells was verified by qPCR. Here, a 399-bp mtDNA 
product that spans the region of nt 3153 – nt 3551 (Primer: 
5´TTCACAAAGCGCCTTCCCCCGT and 5´GCGATGGTGAGAGCTAAGGTCGGG) and a 




238-bp nuclear DNA product that spans the region of exon 5 (nt 55953445 – nt 55953207) 
of the gene USMG5 (Primer: 5´AGTGTCTTAAGAGTAAAGCTGGCCACA and 5´ 
TTGCCTTTGTTGCATTTTCTACAG) were analyzed. QPCR for the nuclear DNA and 
mtDNA products were performed with 10 ng and 0.5 ng of genomic DNA as template, 
respectively, 0.4 µM of each primer and the GoTaq qPCR Master Mix (Promega, Madison, 
WI, USA) were used, detailed reaction mix preparation is listed as in Table 3 (20 µl per 
reaction).  
Table 3. qPCR reaction mix asssembling 
Component Volume (µl) Final Concentration 
GoTaq qPCR Master Mix (2X) 10 1X 
Forward Primer (10 mM) 0.8 400nM 
Reverse Primer (10 mM) 0.8 400nM 
CXR reference dye 0.2  
Nuclease-Free Water 8.2 
 
The thermal cycling conditions for both nuclear and mtDNA qPCR were listed in Table 4 and 
run in a 7900HT real-time PCR system (Applied Biosystems, Foster City, CA, USA).  
Table 4. qPCR thermal cycling conditions 
Step Cycles Temperature (°C) Time 
Initial polymerase activation 1 95 10 minutes 
Denaturation 1 95 15 seconds 
Annealing and elongation 40 60 60 seconds 
2.10.3 Reverse transcription-quantitative PCR (RT-qPCR) 
2.10.3.1 RNA and protein isolation with TRIzol reagent 
The RNA and protein in the EtBr treated cells were simultaneously isolated from the same 
sample by TRIzol reagent (Sigma-Aldrich). The isolation process with TRIzol was performed 
according to the instruction of the manufacturer with some minor modifications. The detailed 
protocol was shown as follows: The EtBr treated cells in 6-well plates were dissolved in 1 ml 
TRIzol solution per well, lysed by repeated pipetting, then transferred to a new 2 ml tube and 
incubated for 10 min. For phase separation, 200 µl of chloroform was added, the samples 
were covered tightly, shaken vigorously for 15 seconds, and incubated for 5 min at RT, 
followed by centrifugation at 18,000 g for 15 min at 4 °C. After phase separation, the upper 
RNA containing phase was mixed with 500 µl of ice-cold isopropanol, incubated for 10 min 




extraction. The obtained RNA pellet was washed twice using 1 mL of 75% (v/v) ethanol, 
vortexed and then centrifuged at 18,000 g for 5 minutes at 4 °C, the RNA pellet was air-
dried for 10 min at RT, and resuspended in 60 µl of H2O. The purified RNA was quantified 
by using the NanoDrop 1000 spectrophotometer (Thermo Fisher). 
For protein extraction, 1.5 ml of ice-cold isopropanol was added to the remaining lower 
phase, and the samples were incubated overnight at -20 °C to precipitate the proteins. The 
solution was then centrifuged for 15 min at 18,000 g at 4 C. The protein pellet was washed 
twice by the addition of 1 ml 0.3 M guanidinium chloride in 95% (v/v) ethanol, incubation for 
10 min at RT, and subsequent centrifugation for 5 min at 10, 000 g at 4 °C. The pellet was 
washed a second time with 1 ml of ethanol and air-dried for 20 min at RT, dissolved in 100 
µl of 1%SDS and 100 µl 8 M urea in 100 mM Tris-HCl (pH 8.0) solution. The isolated protein 
was quantified by the BCA assay (Thermo Fisher).  
2.10.3.2 Mitochondrial transcripts quantification by RT-qPCR 
Four mitochondrial transcripts, MT-ND5, NDUFS1, UQCRC2, SDHB, were quantified by RT-
qPCR, the SLC1A4 transcript was used as a loading control. Five primer pairs were 
designed by Primer-BLAST (Ye, Coulouris et al. 2012), synthesized by Eurofins Genomics 
(Ebersberg, Germany) and listed in Table 5. All the primer pairs were designed to be 
separated by at least one intron on the corresponding genomic DNA, except for MT-ND5.  
RT-qPCR of the four transcripts was performed with 100 ng RNA template, 0.2 µM of each 
primer and the GoTaq 1-Step RT-qPCR System (Promega) was used. Detailed reaction mix 
preparation is listed as in Table 6 (20 µl per reaction). The thermal cycling conditions for all 
the RT-qPCR reactions were identical as in Table 7 and run a 7900HT real-time PCR 
system (Applied Biosystems). 
Table 5. Primer sequences used to amplify mitochondrial transcripts 
Target 
Primer sequence (5'->3') 












































Table 6. RT-qPCR reaction mix asssembling 
Component Volume (µl) Final Concentration 
GoTaq qPCR Master Mix (2X) 10 1X 
GoScript RT Mix for 1-Step RT-qPCR (50X) 0.4 1X 
Forward Primer (100 µM) 0.04 200nM 
Reverse Primer (100 µM) 0.04 200nM 
CXR reference dye 0.33  
Nuclease-Free Water 9.19 
 
Table 7. RT-qPCR thermal cycling conditions 
Step Cycles Temperature (°C) Time 
Initial reverse transcription 1 37.5 15 minutes 
Reverse transcriptase inactivation and 
polymerase activation 
1 95 10 minutes 
Denaturation 1 95 10 seconds 
Annealing and data collection 40 60 30 seconds 
Elongation 40 72 30 seconds 
 
2.10.4 Western blot 
As described above, the protein of the EtBr treated cells was isolated following the RNA 
extraction with the TRIzol reagent (Sigma-Aldrich). Four mitochondrial complexes subunits, 
three encoded by the nuclear DNA, NDUFS1, SDHB, UQCRC2, and one encoded by the 
mtDNA, MT-ND5, were quantified by western blotting.  In brief, the western blotting was 
performed with the Bio-Rad systems (Hercules, CA, USA) following the manufacturer’s 
instructions. First, the isolated protein was diluted with 4X Laemmli buffer to the desired 
concentration, then boiled at 95°C for 10 minutes. Then, 15 µl of each protein samples 
(containing 2.8 µg protein) were loaded to a 4-15% precast Mini-PROTEAN TGX gel (Bio-
Rad), and run at constant 100 V voltage for about 1 hour in 1X running buffer with a Mini-
PROTEAN electrophoresis system (Bio-Rad). The separated proteins in the gel were then 
transferred to a polyvinylidene fluoride membrane in an ice-chilled transfer buffer by a Mini 
Trans-Blot system (Bio-Rad) at a consistent 350 mA current for about 1 hour. The resulting 
membrane was blocked in 5% BSA in TBST buffer for 1 hour at RT and then incubated in 
the corresponding primary antibody (Table 8) at 4°C overnight. After 5 times wash with 
TBST buffer to remove the residue primary antibodies, the membrane was incubated in the 
secondary antibody at RT for 1 hour. Then the horseradish peroxidase substrate for 
enhanced chemiluminescence was directly applied to the membrane and the images were 




Table 8. Used primary antibodies for the detection of mitochondrial proteins 
Antibodies Manufacturer Catalogue No. 
Anti-MT-ND5 rabbit polyclonal antibody Thermo Fisher PA5-39277 
Anti-NDUFS1 rabbit polyclonal antibody Proteintech 12444-1-AP 
Anti-SDHB rabbit polyclonal antibody Sigma HPA002868 
Anti-UQCRC2 rabbit polyclonal antibody Sigma HPA007998 
2.11 Stable isotopic tracer to quantify the endocytosis in chRCC cells 
The chromophobe RCC cells UOK276 were initially cultured in normal DMEM (Life 
Technologies) supplemented with 10% dialyzed FBS (Thermo Fisher) and 1% PSN 
(Invitrogen) at 37 °C in a humidified atmosphere of 5% CO2. Then the medium was modified 
to EBSS medium containing 13C15N labeled amino acid (13C15N-AA; Cambridge Isotope 
Laboratories, Tewksbury, MA, USA) at the same concentrations of DMEM, 10% dialyzed 
FBS and 1% PSN. UOK276 Cells were grown for ten doublings in the 13C15N-AA medium to 
ensure the full labeling of the intercellular proteins and free AAs. After ten doublings, cells 
were seeded at low cell density in the 6-well plate and switched to 2mL of 1% 13C15N-AA 
medium supplemented with 2.5% BSA. After 5 hours, the medium was removed and 
collected to a new 1.5 ml tube, after being washed twice with ice-cold PBS, the cells in each 
well were added 300 µl of 0.1% triton X100 in PBS and then collected by using a scraper, 
the cell lysate was sonicated for one minute, all the medium and cell lysate were centrifuged 
at 1,000 g for 10 min at 4 °C. After centrifuging, 50 µl of supernatant was taken into a new 
1.5 ml tube, 150 µl methanol and 10 µl IS (3 µM chloramphenicol) were add and vortexed 
for 10 min with the Thermomixer (Thermo Fisher) at 1400 rpm, then centrifuged for 10 min 
at 18,000 g at 4°C, 20 µl of supernatant per run was injected to the LC-MS/MS for analysis. 
To study the inhibition effect of the endocytosis by the PLCG pathway inhibitors, the cells 
were treated for 5 hours with different inhibitors, and then the total amino acids in cells and 
medium were extracted following the above-described protocol and injected to the LC-
MS/MS for relative quantification.  
2.12 ROS measurement method development 
Hydroethidine (HE, D1168) and mito-hydroethidine (mito-HE, M36008) were purchased from 
Invitrogen. Hydropropidine (HPr+) was a kind gift from Prof. Jacek Zielonka, Medical College 
of Wisconsin.  




2.12.1 Synthesis of oxidation products derived from HE, mito-HE, and HPr+ 
The synthesis of oxidation products was done as previously described (Zielonka, Hardy et 
al. 2009). In brief, 2-OH-E+ and 2-hydroxy-mito-ethidium (2-OH-mito-E2+) were synthesized 
by oxidizing HE and mito-HE with potassium nitrosodisulfonate (NDS). E+ and mito-ethidium 
(mito-E2+) were synthesized by reacting HE and mito-HE with chloranil, diethidium (di-E+) 
and di-mito-ethidium (di-mito-E2+) and reacting HE and mito-HE with potassium ferricyanide. 
2-hydroxypropidium (2-OH-Pr2+), propidium (Pr2+), and dipropidium (di-Pr2+) were derived 
from HPr+ and synthesized using a procedure similar to that used to synthesize 
corresponding products from HE (Michalski, Zielonka et al. 2013). 
2.12.2 Generation of MRM methods for fluorogenic probes and derived oxidation 
products and LC-MS/MS conditions 
The educts and oxidation products of the three probes were tuned individually to identify and 
optimize specific transitions for the QTrap 6500 mass spectrometer (Sciex). About 100 
ng/µL of all compounds were dissolved in methanol and a constant flow of 7 µL/min was 
used. The automatic optimization procedure in the analyst software (v.1.6.2) was used. The 
ten most intense fragment masses per compound were optimized for collision energy, 
declustering potential, and the collision cell exit potential (Table 9).  














MRM ion ratio 
HE 316.2 210.1 6.75 76 43 24 1 
HE 316.2 287.1 6.75 76 29 28 0.71 
HE 316.2 271.1 6.75 76 41 14 0.16 
2-OH-E+ 330.2 301.1 4.95 101 37 8 1 
2-OH-E+ 330.2 300.1 4.95 101 55 28 0.93 
2-OH-E+ 330.2 255.1 4.95 101 69 12 0.84 
E+ 314.1 284.1 5.15 1 51 24 1 
E+ 314.1 286.1 5.15 1 39 16 0.80 
E+ 314.1 285.1 5.15 1 37 18 0.69 
di-E+ 313.2 285.1 5.22 141 35 26 1 
di-E+ 313.2 284.1 5.22 141 41 26 0.77 
di-E+ 313.2 299.1 5.22 141 31 10 0.56 
Continued on the next page 


















MRM ion ratio 
mito-HE 316.7 278.1 7.49 1 19 32 1 
mito-HE 316.7 209.1 7.49 1 43 22 0.28 
mito-HE 316.7 183.1 7.49 1 77 16 0.14 
2-OH-mito-E2+ 323.7 300.1 5.53 111 41 14 1 
2-OH-mito-E2+ 323.7 262.1 5.53 111 33 24 0.72 
2-OH-mito-E2+ 323.7 289.1 5.53 111 37 8 0.54 
mito-E2+ 316.1 285.1 5.64 96 31 18 1 
mito-E2+ 316.1 262.1 5.64 96 31 18 0.80 
mito-E2+ 316.1 289.1 5.64 96 37 14 0.61 
di-mito-E2+ 316.1 285.1 5.63 111 31 26 1 
di-mito-E2+ 316.1 262.1 5.63 111 33 22 0.84 
di-mito-E2+ 316.1 345.1 5.63 111 31 26 0.72 
HPr+ 415.3 272.1 4.53 60 49 16 1 
HPr+ 415.3 328.1 4.53 60 25 10 0.25 
HPr+ 415.3 300.1 4.53 60 31 20 0.80 
2-OH-Pr2+ 215.1 266.1 4.42 60 25 24 1.00 
2-OH-Pr2+ 215.1 300.1 4.42 60 23 26 0.75 
2-OH-Pr2+ 215.1 72.0 4.42 60 25 10 0.63 
Pr2+ 207.2 72.0 4.37 60 23 8 1 
Pr2+ 207.2 250.0 4.37 60 25 24 0.64 
Pr2+ 207.2 163.5 4.37 60 21 16 0.40 
di-Pr2+ 413.1 326.1 4.35 111 21 26 1 
di-Pr2+ 413.1 331.1 4.35 111 21 18 0.02 
di-Pr2+ 413.1 213.1 4.35 111 37 20 0.00 
IS 323.1 275.1 5.00 50 20 14 1.00 
IS 323.1 165.0 5.00 50 37 11 0.52 
IS 323.1 83.0 5.00 60 95 9 0.23 
IS, internal standard chloramphenicol; RT, retention time; DP, declustering potential; CE, collision 
energy; CXP, collision cell exit potential; MRM ion ratio, peak areas of all transitions were divided by 
the highest peak area per compound. 
Three different LC columns and several different buffer conditions were used to identify the 
highest peak areas, optimal peak shapes, and retention times, as described previously 
(Gielisch and Meierhofer 2015). Finally, a Reprosil-PUR C18-AQ (1.9 µm, 120 Å, 150 x 




2 mm ID; Dr. Maisch; Ammerbuch, Germany) with the following buffer and run conditions 
were selected for metabolite separation: A1: LC-MS grade water; 0.1% formic acid; B1: LC-
MS grade acetonitrile; 0.1% formic acid. Gradients and flow conditions were as follows: the 
compounds were separated by a linear increase of B1 from 20% to 95% in 8 min and 
maintained at 95% B1 for 1 min. The concentration of B1 was then reduced to 20% in 1 min, 
and this level was maintained until minute 10. All optimized MRM transitions and retention 
times are shown in Table 9.  
Fragmentation patterns of the probes and O·2−-specific products were recorded by a Q 
Exactive HF mass spectrometer (Thermo Fisher) with a high resolution of 60,000. The 
fragment mass identity was verified using ACD Spectrus Processor 2017.2.1 software. 
Assigned fragment masses differed by less than 0.001 Da from theoretically calculated 
masses and assignments are shown in Figure 26. 
2.12.3 Sample preparation for fluorogenic probe stability tests and metabolite 
extraction  
The stability of all three fluorogenic probes was tested in Hank’s solution (Thermo Fisher) to 
evaluate autoxidation rates under cell-free conditions. Each probe (2 µM) was incubated in 
50 µL Hank’s solution for 0, 10, 30, 60, and 150 min under the following three conditions in 
triplicate: 25°C with light, 25°C without light, and 37°C without light. 200 µL acetonitrile and 
20 µL of 1 mM internal standard (chloramphenicol) were added, vortexed (800 rpm) for 5 
min at room temperature and centrifuged at 8,000 g for 5 min at 4°C to extract the probes. 
20 µL of each supernatant was analyzed by LC-MS/MS to evaluate the autoxidation rates.  
2.12.4 Metabolite extraction and determination of ROS status in a cell line 
For proof of principle, ROS signatures were induced or scavenged by chemical treatments 
to detect compartment-specific signals for HE, mito-HE, and HPr+ using the established LC-
MS/MS method. HepG2 cells were treated with two chemical ROS stimuli, H2O2 (100 µM) 
and rotenone (1 µM) for 2 hours, as well as with the ROS scavenger N-acetyl-cysteine 
(NAC, 1 mM) for 20 hours. HepG2 cells were cultivated in DMEM (Life Technologies) 
containing 4.5 g/L glucose, supplemented with 10% FBS (Silantes, Munich, Germany), 1% 
PSN (Invitrogen), at 37 °C in a humidified atmosphere of 5% CO2. Cells were split into 6-well 
plates (9 cm2) and grown to full confluency. After treatment, cells were incubated with either 
2 µM HE, mito-HE, or HPr+ for 30 min at 37 °C in biological triplicates. 
Cells were washed with ice-cold phosphate-buffered saline twice and immediately lysed in 




suspensions were transferred into 1.5-ml black tubes to avoid light exposure and placed on 
ice for further disruption by shear forces induced by 10 repeated injections through a 26G 
cannula. The homogenates were centrifuged for 5 min at 600 g at 4°C.  Supernatants (50 
µL) were mixed with 200 µL acetonitrile and 20 µL 1 mM internal standard (chloramphenicol) 
and placed on a shaker (800 rpm) to allow protein precipitation for 5 min at 4°C. The protein 
precipitate was pelleted by centrifugation at 20,000 g for 10 min at 4 °C, and the resulting 
supernatant was used for LC-MS/MS analysis. 
2.12.5 LC-MS/MS settings for ROS probes and oxidative products quantification 
The supernatant (20 µL) was injected and compounds were separated on an LC instrument 
(1290 series UHPLC; Agilent), coupled online to a triple quadrupole hybrid ion trap mass 
spectrometer QTrap 6500 (Sciex). All transitions and compound-specific settings are shown 
in Table 9. Data acquisition was performed with an ion spray voltage of 5.5 kV in the positive 
mode for the electrospray ionization source, N2 as the collision gas was set to medium, the 
curtain gas was at 30 psi, the ion source gas 1 and 2 was at 50 and 70 psi, respectively, and 
the interface heater temperature was set to 350 °C.  
2.13 Data evaluation and Statistical Rationale 
The metabolite identification in all experiments was based on three levels: (i) the correct 
retention time, (ii) three transitions, (iii) and matching MRM ion ratios of tuned pure 
metabolites as described previously (Gielisch and Meierhofer 2015). Peak integration was 
performed using MultiQuantTM software v.2.1.1 (Sciex). All peaks were reviewed manually 
and adjusted if necessary. The peak area of the first transition per metabolite was used for 
subsequent calculations. An internal standard was used to normalize all LC-MS/MS runs for 
instrumental variations.  
For the proteome and metabolome data sets, a two-sample t-test was performed. Multiple 
test correction was done by Benjamini-Hochberg with an FDR of 0.05 by using Perseus 
(v1.6.0.2) (Tyanova, Temu et al. 2016). Significantly regulated proteins and metabolites 
were marked by a plus sign in the corresponding Supplemental Tables S2 and S3. The 
Mann–Whitney U test was used to determine whether GSH levels from independent urine 
and plasma samples have the same distribution; the p-value significance cut-off was ≤ 0.01. 
 
 




2.14 Data availability 
The datasets generated in the current study are available as supplementary files and in the 
following repositories: 
The WES raw files can be accessed via https://www.ncbi.nlm.nih.gov/sra with the accession 
number: PRJNA413158.  
Proteomics raw data have been deposited to the ProteomeXchange Consortium via the 
Pride partner repository (Vizcaino, Cote et al. 2013) with the dataset identifier PXD010391. 
Metabolomics data have been deposited in the publically available repository PeptideAtlas 
with the identifier PASS01250 and can be downloaded via 
http://www.peptideatlas.org/PASS/ PASS01250. 
Mass spectrometry data of the ROS measurement method development have been 















To comprehensively understand the characteristics of chRCC, two systematic omics 
approaches, mass spectrometry-based proteome, and metabolome profiling in nine chRCC 
and adjacent healthy kidney tissues were employed (Figure 10). In order to verify the correct 
diagnosis of all the chRCC cases, copy number variations (CNV) were retrieved from the 
whole-exome sequencing (WES) data (Xiao, Clima et al. 2019), the typical monosomies of 
chromosomes 1, 2, 6, 10, 13, 17, and 21 were identified in all cases (Figure 11), conforming 
to previous reports (Brunelli, Eble et al. 2005, Haake, Weyandt et al. 2016, Casuscelli, 
Weinhold et al. 2017).  
 
Figure 10. The proteome and metabolome profiling workflow of chRCC.  
(A) The proteome workflow involves tissue lysis of the tumor and kidney samples, followed by protein 
digestion with trypsin, peptide fractionation, analysis on the LC-MS and label-free quantification. (B) 
The metabolomics workflow involves tissue lysis of the tumor and kidney samples, metabolite 
extraction, followed by data acquisition by a targeted LC-MS approach and relative quantification of 
the peaks. 
3.1 Proteome profiling of chRCC 
A total of 26,839 peptides and 3,575 proteins were identified in chRCC samples and 
adjacent healthy kidney tissues from ten patients, both at a false discovery rate (FDR) of 
1%. 56.9% (2,034) of these proteins were quantified in at least six out of nine samples. 
Between different samples, the values of Pearson correlation coefficient ranged from 
ranging from 0.659 to 0.921 in chRCC and 0.770 to 0.955 in kidney tissues. (Figure 12A). A 
principal component analysis (PCA) of the proteome data revealed that the first component 




K9; Figure 12B). These results indicate a higher variability within tumor samples, most likely 
due to the differences in micro-environmental conditions or the heterogeneity of the tumors. 
A t-test with Benjamini-Hochberg (BH) correction (FDR < 0.05) for multiple testing was 
performed to identify significantly altered proteins between chRCC and controls. Altogether 
983 significantly regulated proteins were identified, 390 proteins were significantly up- and 
593 were down-regulated in chRCC (Figure 12C, Supplemental Table S2). Among these 
significantly changed proteins, fructose-1,6-bisphosphatase (FBP1), which was shown to 
oppose clear cell RCC (ccRCC) progression (Li, Qiu et al. 2014), decreased more than 28-
fold in the tumor. Phospholipase C gamma 2 (PLCG2), was over 74-fold increased in 
chRCC, these high transcript expression levels had been considered as a potential 
biomarker for chRCC (Durinck, Stawiski et al. 2015). Thus, the proteomic analysis can verify 
known molecular signatures of RCC and serve as a source for subsequent computational 
analyses. 
 
Figure 11. Exome-based copy number variation analysis in chRCC. 
chRCC specific monosomies of chromosomes 1, 2, 6, 10, 13, 17, and frequently of 21 were identified 






Figure 12. The proteomic analysis of chRCC  
(A) Pearson correlation within the chRCC samples and kidney tissues. (B) A principal component 
analysis (PCA) of the proteome data revealed some outliners. (C) A volcano plot of log2 abundance 
ratios of chRCC versus kidney tissues (n =9) against the -log10 (p-value) of the proteome. Altogether 
390 proteins were significantly up-regulated and are shown in red; 593 proteins were significantly 




A gene set enrichment analysis (GSEA) (Subramanian, Tamayo et al. 2005) was employed 
to assess whether an a priori defined set of proteins show statistically significant, concordant 
differences between chRCC and healthy kidney tissues. GSEA revealed several significantly 
(p ≤0.01 and FDR ≤ 0.05) regulated Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways in chRCC versus healthy tissues (Figure 13, Table 10, Table 11). The up-
regulated pathways included the proteasome, ubiquitin-mediated proteolysis, the lysosome, 
and phagocytosis, in chRCC compared with normal tissue (Figure 13, Table 10). In contrast, 
pathways involved in energy supply chains and nutrition homeostases, such as lipid 
metabolism, GSH metabolism, the peroxisome, glycolysis and gluconeogenesis, and amino 
acid metabolism pathways were significantly down-regulated in chRCC (Figure 13, Table 
11). 
 
Figure 13. Gene set enrichment analysis of the proteome revealed regulated pathways in 
chRCC.  
Protein pathway analysis of chRCC versus kidney controls. Indicated are significantly (p ≤0.01 and 
FDR ≤ 0.15) enriched (red) and decreased (blue) KEGG pathways in chRCC. Grey lines connect 
overlapping pathways. Similar pathways are circled by a dotted line, such as decreased amino acid-, 






Table 10.  Gene set enrichment analysis of the chRCC proteome, listed are significantly 
upregulated pathways in chRCC. 
KEGG pathway size p-value q-value 
 Lysosome 48 0.00 0.01 
 Vibrio cholerae infection 24 0.00 0.01 
 Ubiquitin mediated proteolysis 18 0.00 0.01 
 FC gamma r mediated phagocytosis 21 0.00 0.02 
 Proteasome 32 0.00 0.02 
 Epithelial cell signaling in helicobacter pylori infection 20 0.00 0.01 
 
Table 11. Gene set enrichment analysis of the chRCC proteome, listed are significantly 
downregulated pathways in chRCC. 
KEGG pathway size p-value q-value 
Glycine serine and threonine metabolism 21 0.00 0.00 
Beta alanine metabolism 16 0.00 0.00 
Metabolism of xenobiotics by cytochrome P450 17 0.00 0.00 
Valine leucine and isoleucine degradation 40 0.00 0.00 
Peroxisome 32 0.00 0.00 
Drug metabolism cytochrome P450 20 0.00 0.00 
PPAR signaling pathway 29 0.00 0.00 
Arachidonic acid metabolism 13 0.00 0.00 
Tryptophan metabolism 24 0.00 0.00 
Glutathione metabolism 27 0.00 0.00 
Histidine metabolism 12 0.00 0.00 
Fatty acid metabolism 31 0.00 0.00 
Phenylalanine metabolism 10 0.01 0.01 
Tyrosine metabolism 16 0.00 0.01 
Ascorbate and aldarate metabolism 10 0.00 0.01 
Pentose and glucuronate interconversions 10 0.01 0.01 
Glycolysis gluconeogenesis 38 0.00 0.01 
Butanoate metabolism 23 0.00 0.01 
Alanine aspartate and glutamate metabolism 17 0.01 0.01 
Lysine degradation 18 0.00 0.01 
Retinol metabolism 11 0.00 0.02 
Arginine and proline metabolism 27 0.01 0.02 
Propanoate metabolism 27 0.01 0.02 
Proximal tubule bicarbonate reclamation 10 0.01 0.02 
Glycerolipid metabolism 13 0.03 0.04 







3.2 Metabolome profiling of chRCC 
Metabolite identification was based on three very strict criteria to exclude false-positive 
result, (i) the correct retention time, (ii) up to three MRMs, and (iii) a matching MRM ion peak 
ratio of tuned pure metabolites as a reference (Gielisch and Meierhofer 2015). Targeted 
metabolome profiling, targeting a panel of 366 metabolites, was performed in chRCC. 144 
metabolites were identified and relatively quantified (Figure 14, Supplemental Table S3). A 
statistical analysis using a two-sample t-test with the BH (FDR of 0.05) correction for 
multiple testing revealed 28 significantly (p-value <0.01) regulated metabolites (19 down-, 9 
up-regulated) in chRCC versus kidney tissues (Figure 14). The top three significantly up-
regulated metabolites are all related to GSH metabolism (including both oxidized and 
reduced GSH, the GSH precursor gamma-glutamylcysteine; Figure 14, Supplemental Table 
S3), consistent with a previous study performed in chRCC (Priolo, Khabibullin et al. 2018). 
Interestingly, a similar pattern was also reported in other RCC subtypes, including ccRCC 
(Hakimi, Reznik et al. 2016), pRCC (Al Ahmad, Paffrath et al. 2019), and RO (Kurschner, 
Zhang et al. 2017, Gopal, Calvo et al. 2018), thus the up-regulation of GSH has been 
proposed as a hallmark of kidney cancer and can be exploited as a specific treatment 
strategy (Xiao and Meierhofer 2019).  
 
Figure 14. Quantified metabolites by 
targeted metabolome profiling of chRCC. 
The distribution of fold changes of 144 
metabolites in this cohort (n=9) of chRCC 
versus kidney tissues. Significantly (FDR 
<0.01) up-regulated and down-regulated 
metabolites are shown in red and blue, 





3.3 Proteomic analysis reveals the downregulation of OXPHOS in chRCC 
The loss of CI and consequently the compensatory increase of the other OXPHOS 
complexes are the main molecular hallmarks of RO (Simonnet, Demont et al. 2003, Mayr, 
Meierhofer et al. 2008, Kurschner, Zhang et al. 2017, Gopal, Calvo et al. 2018) The 
proteome data were used to explore, whether chRCC also has similar impaired 
mitochondrial features. A general decrease of subunits involved in all OXPHOS complexes 
was observed in chRCC relative to the normal kidney, predominantly affecting CI subunits 
(Figure 15A). The average log2 fold change (log2 FC, chRCC VS kidney) was -1.79 for CI, -
1.05 for CII, -0.91 for CIV, -0.57 for CV, and only CIII was unchanged (-0.03) (Figure 15A). A 
comparison with the proteome data of RO (Kurschner, Zhang et al. 2017) revealed that only 
CI subunits were similarly downregulated in both tumors, whereas the protein abundance of 
all other OXPHOS complexes was increased in RO, but decreased in chRCC (Figure 15B). 
It is worth noting that the mitochondrial mass accumulation, a histological hallmark of RO, 
was consistently reflected by an allocation analysis of the proteome data, as the 
mitochondrial proteins show an obvious shift towards the upregulation direction (Figure 
15D). This result further confirmed the complete loss of CI in RO, considering that the 
accumulated mitochondrial mass should lead to an increase of all the constituting 
mitochondrial proteins. However, the allocation analysis of the chRCC proteome did not 
show any remarkable shift of the mitochondrial proteins (Figure 15C), which indicates the 
chRCC cases in this cohort did not have the mitochondrial accumulation feature, thus the 
downregulation of OXPHOS did not result from the alteration of mitochondrial amount in 
chRCC relative to normal kidney. 
The proteomic analysis of chRCC and comparison with RO revealed a significant 
diminishment of CI in both tumors, whereas an opposite regulation of the other OXPHOS 
complexes, upregulated in RO, but downregulated in chRCC. Such distinct regulation of 
OXPHOS has the potential to be developed as a diagnostic marker for distinguishing 





Figure 15. Distinct regulation of the OXPHOS complexes in chRCC and RO. 
Comparison of protein abundance ratios (log2) of all OXPHOS subunits between (A) chRCC and (B) 
RO samples versus healthy controls. Displayed are the five OXPHOS complexes, including all 





and RO (Kurschner, Zhang et al. 2017) versus adjacent healthy kidney samples, respectively. The 
color gradient of the subunits reflects a low (blue) or high (red) abundance of this protein in the tumor. 
The abundances of CI subunits were the most decreased in chRCC and RO, whereas all other 
OXPHOS complexes were increased in RO, but generally showing a low abundance in chRCC. 
Assembly factors (fond in bold), not part of the final complex, were increased in both tumor types. The 
symbol * indicates significantly (FDR ≤ 0.05) regulated proteins. (C) The density plot shows the 
density of mitochondrial and non-mitochondrial protein counts versus the log2 fold changes of proteins 
comparing chRCC versus kidney samples. (D) The density plot shows the density of mitochondrial 
and non-mitochondrial proteins versus the log2 fold changes of proteins comparing RO versus kidney 
samples. Proteins located in mitochondria are indicated in red (Human Mito Carta, 1158 entries 
(Calvo, Clauser et al. 2016), whereas non-mitochondrial proteins are shown in blue. 
3.4 ChRCC display a discrepancy between the abundance of genes coding 
for- and the proteins involved in the respiratory chain  
Contrary to the decreased abundance of proteins involved in OXPHOS complexes identified 
by proteome profiling, the transcriptome analysis of chRCC (KICH data set from TCGA) 
found high expression patterns associated with the electron transport chain genes (Davis, 
Ricketts et al. 2014, Ricketts, De Cubas et al. 2018).  A gene set enrichment analysis 
(GSEA) (Subramanian, Tamayo et al. 2005) of all quantified proteins showed a negative 
enrichment score (-0.36) of the KEGG pathway “oxidative phosphorylation” (Figure 16A), but 
a positive enrichment score (0.47) when analyzing with the transcriptome data (Figure 16B). 
Therefore, a correlation analysis of the proteome and transcriptome data was performed 
and a high overall correlation between the proteins and transcripts with a Pearson’s 
correlation coefficient of 0.671 was found (Figure 16C). However, the protein abundances of 
OXPHOS subunits were identified to have a poor correlation with their corresponding RNA 
expression with a Pearson correlation coefficient of 0.196 (Figure 16C).  
To validate the biological significance of the contradictory regulation between the 
transcriptome and proteome, the enzymatic activities of all respiratory chain complexes and 
citrate synthase (CS) were measured and the activities were compared for chRCC and the 
adjacent matching healthy tissues. This analysis revealed a significant reduction in the 
enzyme activities of CI, CII, CIV, and CV in chRCC, whereas CIII was unchanged and the 
activity of the TCA cycle enzyme CS was significantly increased (Figure 16D-I).  
Thus, the enzymatic activities of the respiratory chain reflect the abundance of protein rather 
than the expression of RNA transcripts. The TCA cycle, which is involved in many different 




significantly increased in chRCC. Nevertheless, the abundance of “energy carriers”, such as 
NAD+, NADH, NADP, ATP, and ADP was unchanged (Supplemental Table S3).  
 
Figure 16. Comparison of the RNA expression versus the protein abundance between chRCC 
and kidney controls. 
A pathway analysis (GSEA) shows the down-regulation of OXPHOS on the proteome level (this 





OXPHOS transcripts versus proteins as log2 fold changes (blue dots) and specific entities involved in 
OXPHOS (red triangles), which display the discrepancy between the expression of transcripts and 
protein abundance. RNA data were retrieved from TCGA. (D to H) Enzyme activities (nmol/min/mg 
protein, n = 9) of the OXPHOS complexes in chRCC were compared with kidney controls. (D) 
Complex I (CI), (E) Complex II (CII), (F) Complex III (CIII), (G) Complex IV (CIV), (H) Complex V 
(CV), and (I) citrate synthase (CS). P-values in (D-I) are *P < 0.05, **P < 0.01, and ***P < 0.001 by 
paired t-test. n.s., not significant. 
3.5 ChRCC are characterized by an increased level of GSH and reduced 
protein abundance of GSH degrading enzymes 
Reactive oxygen species (ROS), acting as a double-edged sword in cancer cells, are mainly 
produced within the respiratory chain in a cell, predominantly by CI and CIII (Chen, Vazquez 
et al. 2003, Li, Ragheb et al. 2003). The main intercellular ROS scavenger GSH and its 
related metabolites boosted in RO as an adaptive event following the loss of CI (Kurschner, 
Zhang et al. 2017, Gopal, Calvo et al. 2018). Similarly, the top three increased metabolites 
in chRCC were all involved in GSH metabolism, including GSH (115-fold), glutathione 
disulfide (GSSG, 54-fold), and γ-glutamylcysteine (15-fold; Figure 17A-C, Supplemental 
Table S3). Case-specific GSH/GSSG ratios were found to be increased in all chRCC 
samples, except for case 4 (Figure 17D). This indicates a reduced oxidative stress burden in 
most chRCC cases, created by at least a hundredfold higher GSH and GSSG levels in 
chRCC compared with the kidney. In contrast to the significantly increased GSH-related 
metabolites, the GSH metabolism pathway was found significantly (p ≤ 0.005) reduced by 
the GSEA analysis of the chRCC proteome data (Figure 13, Table 11). This was mainly due 
to decreased levels (average 42-fold) of GSH degrading and conjugating enzymes, such as 
GGT1, GGT5, GSTM2, GSTM3, GSTA1, ANPEP as well as GPX3 (Figure 17E), which 
catalyzes the reduction of hydrogen peroxide. However, the two key enzymes involved in 
GSH synthesis (GSS, GCLC) were not significantly changed, other GSH related enzymes, 
the GSH peroxidases (GPX1, GPX4), the GSH S-transferases (GSTO1, GSTP1), and the 
GSH reductase (GSR), all remained unchanged or insignificantly increased at a neglected 
level (Figure 17E). Therefore, the boosted level of GSH-related metabolites in chRCC is due 
to significantly reduced abundance levels of proteins involved in GSH degradation, rather 





Figure 17. The level of glutathione boosted in ChRCC. 
Relative abundances of metabolites involved in the glutathione metabolism are shown for normal 
kidney samples and chRCC. (A) Reduced glutathione, (B) Oxidized glutathione, and (C) γ-
glutamylcysteine. (D) GSH/GSSG ratio was calculated with the relative signal intensities. (E) 
Heatmap of all the quantified proteins involved in glutathione metabolism in chRCC, the color gradient 
of the proteins indicates a low (blue) or high (red) log2 fold change of this protein in chRCC versus 
normal kidney tissues. P-values in (A) to (C) are **P < 0.01, and ***P < 0.001 by two-tailed Student’s 
t-test. A.U., arbitrary units. 
In a pilot study, the free and total GSH levels in plasma and urine of ccRCC, pRCC, chRCC, 
and RO specimens were further analyzed to elucidate whether GSH can be used as a non-
invasive diagnostic marker. The results clearly indicated that free (Figure 18 A, C) and total 
(Figure 18 B, D) GSH did not show significantly different levels in these tumors and thus 
cannot serve as a non-invasive metabolic marker to distinguish between renal tumor types 






Figure 18. Glutathione levels in plasma and urine cannot be used as a marker to distinguish 
RCCs from controls.  
The free and total GSH levels in plasma (A, B; 6 RO, 6 ccRCC, 12 pRCC, 6 chRCC, and 6 healthy) 
and urine specimens (C, D; 8 RO, 20 ccRCC, 19 pRCC, 7 chRCC, and 20 healthy) specimens were 
measured. Urine samples were normalized to creatinine. P-values are *P < 0.01 by Mann–Whitney U 
test. 
3.6 The decrease of mtDNA content other than CI mutations may lead to a 
malfunction of OXPHOS in chRCC 
To examine whether mtDNA mutations are the main cause of the OXPHOS dysfunction in 
chRCC, as observed in RO (Simonnet, Demont et al. 2003, Gasparre, Hervouet et al. 2008, 
Mayr, Meierhofer et al. 2008, Kurschner, Zhang et al. 2017, Gopal, Calvo et al. 2018), I 




identify somatic and germline mtDNA mutations in chRCC by pairwise comparison of tumor 
and healthy tissues. Adequate coverage (>99.9%) and quality for reliable mtDNA 
reconstruction and variant calling were found (Supplemental Table S5). Five somatic non-
synonymous events were identified with a high disease score (>0.7), which are potentially 
pathogenic (Figure 19A, Supplemental Table S5), with four events involving CI genes from 
four cases and one event involving CIV. Case 4, the only case with a lower GSH/GSSG 
ratio, harbored the somatic mutation in MT-ND5 (>60% heteroplasmy), this mutation might 
lead to inactivation of the associated protein based on the previous functional studies in RO 
(Simonnet, Demont et al. 2003, Gasparre, Hervouet et al. 2008, Mayr, Meierhofer et al. 
2008, Kurschner, Zhang et al. 2017, Gopal, Calvo et al. 2018). Considering the other events 
were present at very low heteroplasmic rate (2 events below 30% and the other 2 around 
5%) (Figure 19A, Supplemental Table S5), and the other chRCC cases did not present any 
non-synonymous CI mutations (Supplemental Table S5), this result suggests that there 
might be other mechanisms leading to the dysfunctional OXPHOS complexes and boosted 
GSH level besides the loss-of-function mutations in CI in RO and some chRCC cases.   
The ρ0 cells, which are cells entirely depleted of mtDNA, showed a severe reduction of all 
proteins involved in the respiratory chain (Aretz, Hardt et al. 2016). Furthermore, lower 
mtDNA copy was observed in chRCC previously (Meierhofer, Mayr et al. 2004), thus a 
decrease in mtDNA copy might be directly related to the abundance decrease of OXPHOS 
subunits. Therefore, to access the mtDNA copy number in chRCC, the mtDNA reads 
between chRCC and controls were compared, as the read depth in a specific region of the 
genome is roughly proportional to the copy number of the DNA region. Indeed, a significant 
decrease (3-fold) of mtDNA read depth in chRCC relative to the normal kidney was identified 
(Figure 19B), indicating lower mtDNA content in chRCC compared with normal kidney. 
Based on these results, I proposed that the downregulation of the OXPHOS might be 







Figure 19. Identified somatic mtDNA mutations and mtDNA copy number evaluation in chRCC. 
(A) Somatic mtDNA mutations with a high disease score (>0.7) were only found in five tumors, only 
the MT-ND5 mutation in case 4 has a relevant heteroplasmy rate. (B) The significantly decreased 
mtDNA read depth indicates a lower mtDNA copy number in chRCC compared to normal kidney (n = 
9). P-values in (B): *P < 0.05 by paired t-test. 
3.7 A low mtDNA content causes the downregulation of OXHPOS subunits 
and elevation of GSH levels 
To investigate the influence of mtDNA content on the OXPHOS complexes, the well-
characterized chRCC cell line UOK276 (Yang, Vocke et al. 2017) was chronically exposed 
to a low dose of ethidium bromide (EtBr, 100 ng/ml) for 19 days to deplete the mtDNA 
(Yang, Vocke et al. 2017). During this process, the EtBr treated cells were carefully 
monitored and samples were collected on days 0, 2, 5, 8, 13, and 19 for the later on 
analysis.  
As expected, the mtDNA content in EtBr treated cells decreased dramatically within 5 days 
and reached ρ0 status (mtDNA completely depleted) in 13 days (Figure 20A), demonstrating 
a successful ρ0 cell line generation. Meanwhile, four OXPHOS subunits, MT-ND5 (CI, 
mtDNA-encoded), NDUFS1 (CI, nuclear-encoded), SDHB (CII), and UQCRC2 (CIII), 
representing different OXPHOS complexes and including both mtDNA and nuclear DNA 
coded subunits, were all downregulated in a time-dependent manner, and showed almost 
undetectable signals after 13 days (Figure 20B), indicating a direct correlation between the 
mtDNA depletion and the decrease of proteins involved in the respiratory chain. 
Metabolome profiling was applied to address the question, whether the GSH levels would 




levels increased remarkably throughout the mtDNA depleting process, reaching its plateau 
already on day 13 (Figure 20C). Interestingly, the corresponding transcripts of the four 
quantified OXPHOS subunits showed different expression patterns, divided into two 
categories. The nuclear-encoded transcripts NDUFS1, SDHB, and UQCRC2 showed a 
decreased expression in 8 days for NDUFS1 and in 13 days for the latter two but then 
started to increase after reaching their lowest levels (Figure 20D), not correlating to their 
protein levels (Figure 20B). Distinguishably, the mtDNA-encoded transcript MT-ND5, 
dropped strikingly in just 2 days without resurgence afterward (Figure 20D), matching 
consistently to its protein abundance (Figure 20B).  
In conclusion, these results indicate that the decrease of the mtDNA content is the main 
cause of the OXPHOS impairment in chRCC. This leads to GSH elevation and a poor 
correlation between the proteins and transcripts of nuclear-encoded OXPHOS subunits, 






Figure 20. Correlation between the mtDNA content with proteins and transcripts for the 
respiratory chain and glutathione levels. 
(A) The mtDNA content monitored over time during ethidium bromide (EtBr) treatment (100 ng/ml) in 
the chRCC cell line UOK276. These cells were used for all subsequent analyses. (B) Western blot 
analysis of the mitochondrial and nuclear-encoded OXPHOS subunits MT-ND5, NDUFS1, SDHB, 
and UQCRC2, showed a time-dependent abundance decrease. (C) The GSH level in chRCC cells 
increased and anti-correlated with the simultaneous decrease in the mtDNA content over time. (D) 
The nuclear DNA-encoded transcripts, NDUFS1, SDHB, and UQCRC2, initially decreased but started 
to increase after reaching their lowest points. The mtDNA-encoded transcript MT-ND5 dropped 
strikingly within 2 days, paralleling the level of mtDNA content without increasing again afterward. P-




3.8 Gluconeogenesis was completely stalled in chRCC 
The KEGG pathway “glycolysis and gluconeogenesis” was significantly reduced in chRCC 
(Figure 13, Table 11). This pathway describes two opposing metabolic functions: the 
generation of pyruvate from glucose and vice versa. Thus, a more detailed view of each 
metabolic pathway showed that the abundance of all glycolytic enzymes were either 
unchanged or slightly increased, whereas all enzymes solely involved in gluconeogenesis 
were greatly reduced in chRCC, such as PC (124-fold), PCK1 (96-fold), PCK2 (996-fold), 
ALDOB (922-fold), and FBP1 (29-fold; Figure 21A). The two aldolase isoforms A and C, 
which were increased in chRCC, have a high affinity for fructose-1,6-bisphosphate (F-1,6-
BP) to foster glycolysis, whereas the highly diminished isoform B has a low affinity for F-1,6-
BP and hence converts the back-reaction from glyceraldehyde-3-phosphate to F-1,6-BP 
(Penhoet, Rajkumar et al. 1966). Furthermore, the decreased PC, which is the main entry 
point for pyruvate to the TCA cycle, shows that the tumor relies on lactate fermentation, also 
indicated by significantly increased LDHA (3-fold) levels in chRCC. These are therefore the 
most relevant metabolic changes observed in the tumor and can be regarded as a hallmark 
of chRCC. A comparison with gene expression data, extracted from The Cancer Genome 
Atlas (TCGA) database (Davis, Ricketts et al. 2014), showed similar results, a significant 






Figure 21. Stalled gluconeogenetic pathway in chRCC. 
(A) Protein abundances of the metabolic pathways glycolysis and gluconeogenesis in chRCC. Log2 
fold changes are displayed between chRCC and kidney tissues, up-regulated proteins are shown in 
red and down-regulated proteins in blue. The symbol * indicates significantly regulated proteins. (B-F) 
Transcript expression (TCGA) of gluconeogenic genes between chRCC (n= 66) and controls (n=25). 
(B) FBP1, fructose-1,6-bisphosphatase 1. (C) ALDOB, fructose-bisphosphate aldolase B. (D) PCK1, 
phosphoenolpyruvate carboxykinase, cytosolic. (E) PCK2, phosphoenolpyruvate carboxykinase, 
mitochondrial. (F) PC, pyruvate carboxylase. The data in (B-F) were calculated by RNA-Seq by 




3.9 ChRCC feature a depletion of amino acid intermediates and pathways 
involved in amino acid metabolism 
On the proteome level, nine distinct pathways involved in amino acid metabolism were 
significantly down-regulated in chRCC (Figure 13 and Table 11). In total, 86 out of 101 
proteins involved in amino acid metabolism showed a decreased abundance (average 22-
fold). Altogether 15 proteins even decreased in abundance by over 40-fold (PHGDH, 
PSAT1, MAOB, DMGDH, SHMT1, BHMT, GATM, EHHADH, DPYS, ABAT, FTCD, DDC, 
ALDH4A1, ASS1, and AGMAT), indicating a major metabolic change (Figure 22A). In 
addition, five pathways associated with fatty acid metabolism were significantly down-
regulated (Figure 13, Table 11), including fatty acid metabolism and the peroxisome, the 
main organelle for fatty acid oxidation.  
The abundances of amino acid intermediates were found to be among the highest depleted 
metabolites in chRCC, matching the decreased protein abundances of amino acid 
pathways. These included guanidoacetic acid (intermediate of multiple amino acids, glycine, 
serine, threonine, arginine, and proline), kynurenic acid (tryptophan intermediate), 
indoleacetic acid (tryptophan intermediate), ureidopropionic acid (beta-alanine intermediate), 
hippuric acid (glycine intermediate), salicyluric acid (glycine intermediate) and 
acetylglutamine (glutamine intermediate), which were the most decreased metabolites in 
chRCC (Figure 22B-G, Supplemental Table S3). Interestingly, the level of glycine was not 
significantly decreased, but all of the other amino acids were either unchanged or slightly, 
but not significantly increased (Supplemental Table S3).  
These data indicate a substantial change in the supply of nutrition in chRCC. The amino 
acid levels are within the normal range, but they originate from external sources through 






Figure 22. Regulation of amino acid metabolism in chRCC. 
(A) A protein-protein interaction network was created to elucidate the regulation of the entire amino 
acid metabolism in chRCC. The colors of the nodes correspond to the protein expression fold change 
comparing chRCC versus healthy kidney tissues; red indicates higher expression and blue lower 
expression in chRCC. The size of the nodes corresponds to the absolute protein expression fold-
change. (B-G) The relative abundance of six selected amino acid intermediates is shown for kidney 




acid. (F) Salicyluric acid. (G) Acetylglutamine. P-values in (B) to (G) are: **P < 0.001, ***P < 5e-4 by 
two-tailed Student’s t-test. A.U., arbitrary units. 
3.10 ChRCC cells feed on extracellular macromolecules via endocytosis 
Pathways related to amino acid metabolism were significantly downregulated in chRCC 
(Figure 13, Figure 22), whereas all detected amino acid levels were unchanged 
(Supplemental Table S3). Thus, I hypothesized that chRCC cells could preferentially 
internalize and catabolize external macromolecules as a source of amino acids. Indeed, a 
pathway related to endocytosis (Fc gamma R mediated phagocytosis) and three protein 
degradation pathways (lysosome, ubiquitin-mediated proteolysis, and proteasome) were 
significantly up-regulated in chRCC (Figure 13, Table 10). In particular, the two lysosome 
markers, LAMP1 and LAMP2, were up-regulated by 3 and 7-fold, respectively 
(Supplemental Table S2). Activated lysosomes indicate that the recycling of 
macromolecules and maintaining an acidic tumor microenvironment favors the viability and 
progression of chRCC. These metabolic changes indicate that extracellular biomass 
recruitment and protein degradation is the preferred way of gaining mass and nutrition in 
chRCC.  
To further investigate, whether increased abundances of lysosomal proteins correlate with 
increased enzymatic activities in chRCC, the activities of two lysosomal enzymes were 
measured, hexosaminidase A and B. These enzymes are involved in the breakdown of 
gangliosides and were both found to be significantly increased in chRCC (Figure 23A-B).  
Next, I asked, whether the supplementation of a macromolecule indeed enhances the 
growth rate of chRCC cells and whether this is mirrored by the alteration of protein 
abundances in endocytosis pathways. Therefore, the proliferation of the chRCC-derived cell 
line UOK276 (Yang, Vocke et al. 2017) and normal kidney cells (HK-2) under different 
amino acid and bovine serum albumin (BSA) concentrations were evaluated. Overall, both 
UOK276 and HK-2 cells grew significantly faster under all amino acid concentrations when 
supplemented with 2.5% BSA, only the UOK276 cells grew equally well when feeding with 
10% amino acids (Figure 23C-D). UOK276 cells proliferated normally under a low amino 
acid concentration of 1% and the addition of 2.5% BSA, whereas HK-2 cells significantly 
reduced the growth rate. This result suggests that UOK276 cells have a higher potential to 
utilize BSA to compensate for the amino acid depletion. Proteome profiling between 
UOK276 cells supplemented with 1% amino acids and with the addition of 2.5% BSA versus 





endocytosis and recycling, Reactome) and the lysosome (KEGG) (Figure 23E, 
Supplemental Table S6). Enzymatic activity measurement of the lysosomal 
hexosaminidases A and B of UOK276 cells between the before mentioned conditions further 
confirmed that external macromolecules triggered the internalization and the degradation 
pathways to break down macromolecules enzymatically via endocytosis (Figure 23F-G), 
which indicates the adaption of chRCC cells to nutrient-poor conditions. Hence, the 
experiments performed in the chRCC derived UOK276 cell line validated the observations 






Figure 23. ChRCC cells activated endocytosis when amino acids were depleted. 
(A-B) Enzymatic activities (nmol/min/mg protein, n =9) of the hexosaminidase A (A) and B (B) in 





cells (D) under different amino acid (AA) and bovine serum albumin (BSA) concentrations normalized 
to complete medium. (E) A pathway analysis (GSEA) of the proteome shows the up-regulation of the 
lysosome and endocytosis in UOK276 cells in 1% amino acid and 2.5% BSA versus a complete 
medium, enriched pathway cutoff, p < 0.01, FDR < 0.25. (F-G) Enzymatic activities (nmol/min/mg 
protein, n =3) of the hexosaminidase A (F) and B (G) in UOK276 cells in complete medium without 
supplementation of BSA and 1% amino acids with 2.5% BSA. The data in (C-D) and (F-G) are 
expressed as means ± SD, p-values in (A-B) are: **P < 0.01, by paired t-test; P-values in (F-G) are: 
*P < 0.01, **P < 0.01, two-tailed Student’s t-test.  
3.11 Pharmaceutical inhibition of the PLCG/IP3/Ca2+/PKC pathway suppresses 
the endocytosis in chRCC  
Phosphatidylinositol phospholipase C gamma 2 (PLCG2) is a membrane protein which 
catalyzes the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG), IP3 further activate the IP3 receptor on the 
endoplasmic reticulum to release Ca2+, which further activate protein kinase C (PKC). The 
protein and RNA abundance of PLCG2 were found to be highly significantly upregulated in 
chRCC, relative to normal kidney tissues (Figure 24A). To investigate the role of PLCG2 and 
its downstream effector IP3/Ca2+/PKC pathway in endocytosis, I developed an LC-MS 
method by using isotope tracers (Figure 24B). First, cells are cultured for multiple 
generations in medium containing uniformly 13C and 15N-labeled amino acids (13C15N-AA) to 
completely label all the intracellular amino acids and proteins. Then, cells are switched to 
13C15N-AA medium supplemented with 2.5% unlabeled BSA. At this point, unlabeled BSA is 
then internalized and degraded in cells, unlabeled amino acids are released or stayed 
intracellularly for protein synthesis. By measuring the amount of the unlabeled essential 
amino acids within the medium and cells, it is possible to access the endocytosis level under 
different conditions or in different cell lines. Using this method, EIPA (a widely used 
endocytosis inhibitor), U73122 (a general inhibitor of PLCG), and 2-APB (an IP3R 
antagonist) were first applied to UOK276 cells, as shown in Figure 24C, leucine, and lysine, 
the two most abundant essential AAs in BSA, were both significantly decreased in the 
inhibitors treated cells, all the other essential AAs were also showed the same trends 
(Figure 25A). In addition, the abundance of leucine and lysine was also significantly 
deduced in UOK276 cells when using BAPTA-AM (a cell membrane-permeable Ca2+ 
chelator) and bisindolylmaleimide I (a PKC inhibitor) (Figure 24D), the same decreases were 
observed in the other essential AAs (Figure 25B). Taken together, these results suggest that 





Figure 24. Chemical inhibition of the PLCG pathway decreases the endocytosis of protein in 
chRCC cells. 
(A) Protein intensity and RNA RSEM plot show that the protein intensity and RNA abundance of 
PLCG2 are significantly increased in chRCC relative to normal kidneys.  (B) The diagram of using 
isotope tracers to quantify protein scavenging by endocytosis with mass spectrometry. (C) The peak 
area plots of leucine and lysine after applying 10 µM EIPA, 30 µM U73122 and 100 µM 2-APB. (D) 
The peak area plots of leucine and lysine after applying 30 µM BAPTA-AM and 3 µM 
Bisindolylmaleimide I. P-values are: *P < 0.05, **P < 0.01, and ***P < 0.001 by two-tailed Student’s t-













Figure 25. Other unlabeled essential amino acids also decrease after chemical inhibition of the PLCG pathway.  
(A) The peak area plots of other unlabeled essential amino acids after applying 10 µM EIPA, 30 µM U73122 and 100 µM 2-APB. (B) 
The peak area plots of other unlabeled essential amino acids after applying 30 µM BAPTA-AM and 3 µM Bisindolylmaleimide I. P-





3.12 The hydroethidine-based probes for ROS measurement have high 
autoxidation rates 
3.12.1 Establishment of an MRM-based method to monitor HE, mito-HE, HPr+, and 
their oxidation products 
To identify and quantify relative differences in the three fluorogenic probes and their 
oxidation products in cell culture systems, a targeted LC-MS/MS approach, based on 
multiple reaction monitoring (MRM) was developed. The mass spectrometry parameters for 
specific transitions of all monitored compounds were individually identified, optimized and 
the three best transitions per metabolite were selected for the final method. The identity of 
fragments was verified by high-resolution mass spectrometry (Figure 26). To increase the 
robustness of the LC-MS/MS method, the correct retention time of all peaks, the peak 
shapes, and the ion ratios were monitored. The ion ratios were calculated by dividing all 
transitions by the largest peak area per compound and the values must match the ratios 
calculated for the pure probes (Gielisch and Meierhofer 2015). All selected transitions, 
including internal standards, were thus combined in a single LC-MS/MS method operating in 
the positive ionization mode (Figure 27A, Table 9). Transitions for the three fluorogenic 







Figure 26. Specific fragment spectra (MS2) obtained for hydroethidine probes and its O·2− 
specific oxidized product.  
(A) HE, (B) its O·2− specific oxidized product 2-OH-E+, (C) mito-HE and (D) 2-OH-mito-E2+, (E) HPr+ 
and (F) 2-OH-Pr2+. Only the three indicated transitions per compound were included in the final MRM 
method that featured high intensities, unique transitions, and no matrix effects. Precursor ions are 







Figure 27. MRM transitions of three fluorogenic probes and their oxidation products, 
separated on a reverse-phase C18 column.  
(A) All transitions were monitored in a single 10 minute LC-MS/MS run; transitions of the most 
important compounds are displayed individually as: (B) HE, (C) 2-OH-E+, (D) mito-HE, (E) 2-OH-mito-
E2+, (F) HPr+ and (G) 2-OH-HPr2+.  
3.12.2 Fluorogenic probe stability is a significant concern 
A mass spectrometry approach overcomes spectral overlap issues in fluorescence-based 
methods, as it relies on the exact masses of specific transitions. Given the natural tendency 
of the probes to undergo autoxidation, the probe stability was firstly monitored. Several time 
series using different light and temperature conditions were performed to monitor the 





conditions, rapid autoxidation rates were observed in all experiments, which translated to an 
increase in the levels of O·2− -specific products (Figure 28). A 150% increase within 60 
minutes was observed for the O·2−-specific products from all three probes under the “25 °C 
without light” condition at this time point (Figure 28A-C). Under standard laboratory light 
conditions, levels of the O·2−-specific products increased by over 200% and after 2 hours to 
more than 300% above initial values (Figure 28D-F). Light conditions had a larger impact on 
O·2−-specific products relative to that seen for temperature increases to 37 °C (Figure 28G-
I). In contrast, the internal standard showed a standard deviation of 5.5 % within all 
experiments, indicating normal variations of the LC-MS/MS runs and in turn robust 
measurement conditions. 
 
Figure 28. Stability tests for fluorogenic probes.  
Probes were incubated in Hank’s solution under (A, B, C) 25 °C without light, (D,E, F) 25 °C with light, 
and (G,H,I) 37 °C without light. Results are based on three biological experiments (*p < 0.05; **p < 




3.12.3 Effects of strong ROS stimulations in cells were smaller than those for 
autoxidation 
HepG2 cells were treated with strong ROS inducers, such as rotenone and H2O2, as well as 
the ROS quencher N-acetyl-cysteine (NAC) (Li, Ragheb et al. 2003, Zmijewski, Banerjee et 
al. 2010), to identify maximum effects in a cell system. I asked whether or not these 
chemical treatments show stronger ROS signals than the autoxidation rates of the probes 
themselves.  
Upon treatment with NAC, levels of all oxidation products did not change significantly, 
except for Pr2+. Indeed, the fold-changes of these oxidation products were slightly reduced 
for HE and HPr+ and unchanged for mito-HE (Figure 29A). After incubating the cells with 
H2O2, levels of O·2−-specific products were unchanged for mito-HE compared to controls and 
even reduced for HE and HPr+ (Figure 29B). Rotenone treatment was associated with 
insignificant reductions in O·2− specific products for HE and HPr+, and only 2-OH-mito-E2+ 
showed a significant increase of 50%. This result was perhaps predictable, given that 
mitochondria are sites of electron leakage (Figure 29C). All harsh treatments did not induce 
significant changes in the amounts of O·2− specific products, most likely because the cell 
culture medium already induced a high oxidation rate of the three probes, which then 
diminished cell-specific changes. 
 
Figure 29. ROS determination of fluorogenic probes after ROS stimulation with chemicals.  
Treatments of (A) 1 mM NAC for 20 hours, (B) 100 µM H2O2 for 2 hours, and (C) 1 µM rotenone for 2 
hours in HepG2 cells. NAC, N-acetyl-cysteine; FC, fold change. Results are based on three biological 
experiments (*p < 0.05; **p < 0.01; ***p < 0.001; two tailed unpaired t-test with control group). Error 
bars, mean ± S.D. 
Together these results indicate that the autoxidation effects of the three probes were high 
upon incubation at 25 °C or 37 °C, especially under standard room light conditions. This 


















The first description of chRCC as a new kidney cancer entity by Thoenes et al. (Thoenes, 
Storkel et al. 1985) was over 30 years ago. Yet, the understanding of this rare tumor type is 
still limited due to its rarity. Recently, two studies, comprising roughly a hundred cases 
(Davis, Ricketts et al. 2014, Ricketts, De Cubas et al. 2018), were undertaken to understand 
the genetic cause of chRCC. In contrast, proteome and metabolome profiling data from this 
malign tumor are still sparse (Valera, Li-Ning et al. 2010, Schaeffeler, Buttner et al. 2018). 
To fill this gap, this thesis employs and integrates proteomics, transcriptomics (from TCGA), 
and metabolomics approaches as well as mitochondrial WES to gain insights into the 
mtDNA mutation landscape and to elucidate pathological alterations between chRCC and 
adjacent kidney tissues. In addition, these results were compared with the RO data from the 
previous study (Kurschner, Zhang et al. 2017) to identify molecular differences between 
these two highly similar tumor entities for the discovery of potential diagnostic markers.  
4.1 The decreased mtDNA content is the main cause of dysregulation of 
OXPHOS in chRCC 
The Warburg effect describes that cancer cells consume high amounts of glucose and have 
high lactate production, even under aerobic conditions (Warburg 1956). Thus, high glycolytic 
activity in company with reduced OXPHOS is found in many cancers. This phenomenon was 
also observed in this chRCC cohort, as chRCC was showed to have an enhanced glycolysis 
pathway, combining with the downregulated OXPHOS found in this study. Previously, a 
significant reduction in all mitochondrial enzyme activity as well as in the mtDNA content 
were found in ccRCC and pRCC (Meierhofer, Mayr et al. 2004), but at this specific point, I 
see a clear difference to benign RO, where only CI subunits and its enzyme activity were 
significantly diminished, while all other complexes and enzyme activities were significantly 
increased (Kurschner, Zhang et al. 2017). 
The most strikingly increased set of metabolites in chRCC were those involved in GSH 
metabolism (GSH, GSSG, and γ-glutamyl-cysteine,). This finding is very similar to previous 
studies in chRCC (Priolo, Khabibullin et al. 2018, Xiao, Clima et al. 2019), pRCC (Al Ahmad, 
Paffrath et al. 2019), RO (Kurschner, Zhang et al. 2017, Gopal, Calvo et al. 2018), and in 
ccRCC (Wettersten, Hakimi et al. 2015, Hakimi, Reznik et al. 2016). Since GSH is an 
important ROS scavenger (Circu and Aw 2008), the increased GSH level and GSH/GSSG 
ratio in chRCC can thus be considered as the main strategy for the tumor to overcome ROS 




glutathione synthesis were unchanged, but enzymes involved in glutathione degradation 
were significantly reduced in chRCC.  
How closely protein abundance corresponds to the transcript level is a fundamental 
question. A discrepancy between increased transcript expression and reduced protein 
abundances of the OXPHOS has been observed not only in this chRCC cohort but also in 
RO (Kurschner, Zhang et al. 2017). This anti-correlation indicates that different levels of 
molecular information are necessary to evaluate and understand a pathogenic mechanism. 
Thus, the enzymatic activities of the OXPHOS in chRCC and RO (Mayr, Meierhofer et al. 
2008) matched to protein abundances rather than to the transcript levels. A study analyzing 
ρ0 cells (cells without mtDNA), showed that the abundance of nuclear-encoded proteins of 
the respiratory chain was significantly reduced (Aretz, Hardt et al. 2016). This indicates that 
the observed discrepancy between proteins and transcripts of OXPHOS in chRCC is mainly 
caused by the reduced mtDNA content in chRCC. This has been further validated by 
monitoring the mtDNA depletion and the abundance of respiratory subunits in a chRCC 
derived cell line over time. A discrepancy between the mtDNA content and nuclear-encoded 
OXPHOS subunits was observed, only mtDNA-encoded transcripts almost entirely 
disappeared, whereas nuclear-encoded were kept stable when the cells reached the ρ0 
status. In addition, the GSH level anti-correlated with the mtDNA decrease, indicating that 
defective respiration causes ROS stress, which is compensated by increasing the main ROS 
scavenger GSH.   
The mitochondrial genomes in RO and thyroid cancers have been shown to have a 
particularly enriched mutation load (Gasparre, Hervouet et al. 2008, Mayr, Meierhofer et al. 
2008, Grandhi, Bosworth et al. 2017). Although diverse potentially pathogenic mtDNA 
mutations with mostly low heteroplasmy loads (except case 4 mutated in MT-ND5 gene with 
>60% heteroplasmy) were identified, I conclude that these low heteroplasmic mtDNA 
mutation most likely do not have any substantial influence to the phenotype of chRCC, as 
these cases did not present different regulations of the OXPHOS and showed the same 
overall proteome. Even though all chRCC cases had similarly increased levels of GSH and 
its related metabolites, case 4 did show a declined GSH/GSSG ratio in chRCC relative to 
the normal kidney, opposite to all the other cases. This result indicates higher oxidative 
stress within the MT-ND5 mutated case. This unique phenomenon might be caused by the 
inclined conversion from GSH to GSSG since excessive ROS is produced when CI is 
deficient because of the MT-ND5 mutations (Mayr, Meierhofer et al. 2008, Leman, Gueguen 





in case 4 along with a decreased mtDNA content specially produced more ROS than the 
other cases. 
A histopathological differentiation of benign RO from malignant chRCC is still difficult, even 
using multiple immunohistochemistry markers (Ng, Morais et al. 2016). There are also case 
reports on rare hybrid tumors (Noguchi, Nagashima et al. 1995), including oncocytic content 
(Pote, Vieillefond et al. 2013) and the rare genetic disorder Brit-Hogg-Dube (BHD) syndrome 
(Vera-Badillo, Conde et al. 2012), where the coexistence of RO and chRCC was shown. 
The accumulated microvesicles in the cytoplasm are a key histological feature in chRCC, 
may originate from defective mitochondriogenesis, but this feature is also not diagnostic, as 
they can also be found in RO and eosinophilic variants of ccRCC (Tickoo, Lee et al. 2000). 
Consequently, the abundance signature of OXPHOS complexes can be used to 
unambiguously distinguish these two tumor species.  
4.2 ChRCC features metabolic reprogramming 
The metabolic reprogramming is a very important hallmark of cancer (Hanahan and 
Weinberg 2011), chRCC was revealed to have substantial reprogramming of the central 
metabolic pathways. The energy-consuming process gluconeogenesis was entirely stalled, 
most likely to circumvent limited nutritional supplies. This seems to be a general mechanism 
in kidney cancer since similar observations were also reported in RO (Kurschner, Zhang et 
al. 2017) and at the transcript level for pRCC (Cancer Genome Atlas Research, Linehan et 
al. 2016) and ccRCC (Li, Qiu et al. 2014). The down-regulation of FBP1, a key player in 
gluconeogenesis, was further linked to ccRCC progression and was shown to inhibit nuclear 
hypoxia inducible factor function (Li, Qiu et al. 2014). This further stimulates the metabolic 
switch by up-regulating the glycolytic target genes upon its loss in the tumor. The effect of 
increasing glycolytic enzymes was also seen in the chRCC proteome data. Of equal 
importance is the uptake of glutamine and glucose to sustain tumor growth, which was 
shown to be significantly lower in chRCC compared with ccRCC and pRCC (Nakajima, 
Nozaki et al. 2017). This could be the consequence of a low microvessel density observed 
in chRCC compared with ccRCC tumors (Jinzaki, Tanimoto et al. 2000). Hence, chRCC 
seems to be poorly supported by classical nutrition supply chains.  
Contrary to the observed abundance decrease of gluconeogenic proteins in chRCC, the 
over-expression of gluconeogenic genes and proteins are frequently found in other tumor 
species. Specifically, increased ALDOB expression was found to favor cancer cell 




2018), rectal cancer (Tian, Hsieh et al. 2017), and colorectal adenocarcinoma (Li, Li et al. 
2017). This might be one reason for the low metastatic potential (Volpe, Novara et al. 2012) 
and the high survival rate observed in the chRCC patients (Amin, Amin et al. 2002, 
Przybycin, Cronin et al. 2011). 
Besides the dramatic reduction in enzymes involved in gluconeogenesis and the OXPHOS, 
a decrease in the proteins of the fatty acid and amino acid synthesis pathways was 
identified in chRCC. One might wonder how this tumor could sustain viability and growth 
with the downregulation of so many key metabolic pathways. However, the actual level of 
amino acids and metabolites, which can be regarded as essential “energy carriers”, such as 
FAD, NADPH, ADP, cyclic AMP, and NAD+ were indeed unchanged, indicating a sufficient 
amount of building blocks and nutrients in chRCC. Only amino acid intermediates were 
decreased in chRCC, reflecting a lower activity of pathways involved in amino acid 
metabolism. In contrast, increased amino acid metabolism was frequently found in other 
cancer types to promote proliferation and metastasis, such as glycine and serine 
metabolism in breast cancer (Jain, Nilsson et al. 2012) and serine biosynthesis in multiple 
cancers (Gromova, Gromov et al. 2015, Jia, Zhang et al. 2016). 
I thus hypothesize that chRCC use other ways than those discussed to acquire nutrition. In 
addition to all of the decreased pathways involved in energy metabolism, the vascular 
ATPases were showed to be increased in chRCC, the lysosome and the proteasome were 
found to be significantly enriched. These results are clues for an alternative nutritional 
supply in chRCC. The modulation of the microenvironment by the acidity of vascular 
ATPases, to acidify and hydrolyze macromolecules to fuel biomass production (Dettmer, 
Hong-Hermesdorf et al. 2006, Repnik, Cesen et al. 2013, Davidson and Vander Heiden 
2017), might be one advantage for chRCC survival and viability. The lysosomes and 
proteasomes are involved in the cell recycling machinery by contributing and delivering new 
biomass via endocytosis, phagocytosis, and autophagy. The downregulations of pathways 
involved in amino acid metabolism paralleled with an increased abundance of the vascular 
ATPases, lysosome, proteasome, ubiquitin-mediated proteolysis, and endocytosis suggest a 
main adaptive mechanism to gain nutrition in chRCC, as a response to poor classical 
nutrition supply chains.  
PLCG2 was one of the highest increased significant proteins identified by proteome profiling 
and its corresponding transcript was also found to be highly upregulated in chRCC relative 
to the healthy kidney tissues (Davis, Ricketts et al. 2014). PLCG2 functions as a membrane 





directly or through stimulating the Ca2+ release from the endoplasmic reticulum. During 
pharmaceutical inhibition of the PLCG2/IP3/Ca2+/PKC pathway, a significant decrease of the 
endocytosis of macromolecules was found in the chRCC cell line. Furthermore, endocytosis 
was reported to suppress cancer cell blebbing and invasion by increasing the cell 
membrane tension and thus reduced the likelihood of mechanical invasion to the 
surrounding tissue (Holst, Vidal-Quadras et al. 2017). This finding further matches the low 
rate (1.3%) of metastatic chRCC cases (Volpe, Novara et al. 2012). 
4.3 ROS measurement with the hydroethidine-based probes should be 
interpreted with caution 
At present, fluorescence- and HPLC-based approaches are frequently used with 
hydroethidine-based probes such as HE, mito-HE or HPr+ to assess the ROS status in cells 
(Robinson, Janes et al. 2006, Zielonka, Hardy et al. 2009, Kalyanaraman, Dranka et al. 
2014). However, such probes have several drawbacks in fluorescence or HPLC 
applications, particularly because of spectral overlap in fluorescence assays and low 
specificity in HPLC methods. In this project, a new LC-MS/MS method was developed that 
can simultaneously detect and quantify these three fluorogenic probes and their 
corresponding oxidation products. This method resulted in a rapid, sensitive and specific 
LC-MS/MS method to elucidate the ROS status in a cell system with spatial resolution. 
Three specific transitions for each of the educts and oxidized products as well as the ion 
ratios between the transitions and the correct retention time were monitored to ensure high 
selectivity. This method eliminates problematic fluorescence spectral overlap that is typical 
of fluorescence-based techniques and the low specificity associated with the use of only 
HPLC-based methods. However, the results indicated that these hydroethidine-based 
probes were intrinsically prone to oxidation. Incubation at 25 °C or 37 °C in the stability test 
led to rapid probe autoxidation, which could complicate the results obtained when these 
probes are used for ROS detection. Accordingly, the harsh conditions used for ROS 
induction and inhibition treatments generated results for the oxidized fluorophores that 
lacked significance and reproducibility. Hence, subtle changes in ROS levels that can occur 
in biological systems and that can be used to achieve new insights into redox homeostasis 
may not be detectable. 
In addition to the instability of hydroethidine-based probes, other inherent characteristics can 
impede ROS detection, including complex chemical reactions, intercalation with DNA, and 




such as hemoglobin and myoglobin, can react with HE and form fluorescent products. 
These chemical reactions can produce many other oxidation products that can compete with 
radical specific products and may influence the amount of detectable O·2−-specific products. 
In addition, the formation of O·2−-specific products could be influenced by peroxidase 
reactions that can interfere with O·2− quantification (Dikalov and Harrison 2014). Meanwhile, 
mito-HE can be translocated to other intracellular organelles that have a higher negative 
membrane potential (Kalyanaraman, Dranka et al. 2014). 
This targeted LC-MS/MS method allows the selective identification and quantification of the 
fluorogenic compounds HE, mito-HE, and HPr and their respective O·2−-specific products. 
However, a high autoxidation rate was also detected for the probes alone in Hank’s solution. 
These findings suggest that, despite the many recent methodological improvements in ROS 
quantification, direct measurements of ROS levels based on hydroethidine probes may be 
inaccurate due to artifactual effects of autoxidation. Experiments performed using these 









In this thesis, three omics approaches, including proteomics, metabolomics, and 
mitochondrial whole-exome sequencing, were employed to characterize chRCC. Based on 
the integrative analyses of these omics data, I conclude that chRCC is a tumor type with a 
rewired metabolism, indicated by the down-regulation of key metabolic pathways, including 
OXPHOS, gluconeogenesis, glutathione metabolism, and all pathways associated with 
amino acid metabolism. Unlike RO, the decrease of mtDNA content rather than CI mutations 
is the main cause of dysfunctional OXPHOS in chRCC. In addition, chRCC depends on 
extracellular macromolecules as an amino acid source by activating endocytosis, which is 
mediated by PLCG2/IP3/Ca2+/PKC pathway. What’s more, I find that using hydroethidine 
probes to measure ROS level is inaccurate due to artifacts caused by autoxidation.  
This work provides novel insights into the rewiring of metabolic pathways in chRCC, 
discovers the distinct regulation of the OXPHOS as a potential diagnostic marker to 
distinguish chRCC from RO, and identifies PLCG2 as a potential therapeutic target to treat 
chRCC. In addition, the ROS measurements based on hydroethidine probes should be 
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